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With each heartbeat, major arteries experience circumferential expansion due to 
internal pressure changes.  This pulsatile force is called “cyclic strain” and has been 
implicated in playing a pivotal role in the genetic regulation of vascular physiology and 
pathology.   This dissertation investigates the hypothesis that in human umbilical vein 
endothelial cells (HUVEC), pathological levels of cyclic strain activate the c-Myc 
promoter, leading to c-Myc transcription and downstream gene induction.  To determine 
expression and time-dependency of c-Myc in HUVEC, mRNA and protein expression of 
c-Myc under physiological (6-10% cyclic strain) and pathological conditions (20% cyclic 
strain) were studied.  Both c-Myc mRNA and protein expression increased more than 
3-fold in HUVEC (P4–P5) cyclically strained at 20%.  This expression occurred in a 
time-dependent manner, peaking in the 1.5–2 hour range and falling to basal levels by 3 
hours.  Subsequently, the mechanism of c-Myc transcription was investigated by using a 
specific inhibitor to modulate c-Myc transcriptional activation.  This compound, obtained 
from the University of Arizona Cancer Center, attenuates cyclic strain–induced c-Myc 
transcription by about 50% by binding to and stabilizing the silencer element in the 
c-Myc promoter.  Having established this reduction in expression, it was investigated 
how these effects modulate downstream genes that are regulated by c-Myc.  The results 
indicate that direct targeting of the c-Myc promoter may decrease stretch–induced gene 
expression of vascular endothelial growth factor (VEGF), proliferating cell nuclear 
antigen (PCNA), and heat shock protein 60 (HSP60).  These findings may help in the 
development of a novel therapeutic opportunity in vascular diseases. 
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According to the Heart Disease and Stroke Statistics published by the American 
Heart Association, cardiovascular disease (CVD) remains the primary cause of mortality 
in both women and men in the United States.  It is estimated that almost 80 million 
American adults (1 in 3) suffer from one or more types of CVD, which includes high 
blood pressure, coronary heart disease, heart failure, and stroke.  Every day, nearly 2400 
Americans die of CVD.  In fact, CVD claims more lives each year than the next four 
leading causes of death (cancer, chronic lower respiratory diseases, accidents, and 
diabetes mellitus) combined.  The estimated direct and indirect cost of CVD for 2007 
exceeds $430 billion [1]. 
As a result of these staggering statistics, numerous studies have attempted to 
characterize the onset and progression of human CVD.  With an enhanced biological 
understanding of the cell cycle events involved in this pathogenesis, it would be possible 
to better treat and/or prevent these diseases.  Although numerous genes have identified 
roles in atherosclerosis, the mechanism of their induction is largely uncharacterized.  
Cyclic strain, which results as a consequence of pulsatile blood flow, is a principal factor 
in the localization of these diseases [2].  Under normal physiological conditions, arterial 
vascular endothelial cells (EC) are continuously subjected to cyclic strain (6–10%).  
When certain pathological conditions arise in vivo, such as hypertension, atherosclerotic 
plaque development, and intracoronary stenting, elevated cyclic strain (~20%) can induce 
vessel remodeling, leading to a pro-atherogenic endothelium [2, 3].  By implementing an 
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in vitro cyclic strain model, it is possible to mimic some of the hemodynamic conditions 
associated with atherosclerosis and thereby study it from a mechanistic point of view. 
Recently, in an attempt to study the transcriptional changes that occur in 
vasculoproliferative vascular diseases, research has turned to finding parallel pathological 
mechanisms in cancer.  These findings have identified the oncogene c-Myc, known to be 
involved in the modification of cell cycle-related events (proliferation, differentiation, 
and apoptosis), as a potential research target.  This project will examine the functional 
contributions of c-Myc to the human EC cyclic strain response in an attempt to add 
insight into the pathogenesis of atherosclerosis/restenosis.  This dissertation proposes that 
pathological levels of cyclic strain activate the c-Myc promoter, leading to c-Myc 
transcription and downstream gene induction, which, in sum, contribute to the 
development of cardiovascular disease.  If true, these findings will help to develop a 
novel therapeutic opportunity in occlusive vascular diseases. 
 
1.2 Hypothesis and Specific Aims 
 
The principal goal of this project was to investigate the genetic expression of 
human umbilical vein endothelial cells (HUVEC) in response to applied mechanical 
stretch.  Specifically, in order to model the circumferential expansion of arteries in vivo, 
HUVEC were subjected to uniaxial, cyclic strain in vitro.  The overall hypothesis for this 
research, as outlined in the original thesis proposal, was: 
 
Pathological levels of cyclic strain activate the c-Myc promoter, leading to c-Myc 
transcription and downstream gene induction, which, in sum, contribute to the induction 
of vascular obstructive diseases. 
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To evaluate this general hypothesis, the following three specific aims were formulated: 
 
 
Specific Aim 1: Determine the expression and time-dependency of c-Myc in human 
umbilical vein endothelial cells subjected to cyclic strain 
This aim will investigate the mRNA and protein expression of c-Myc under pathological 
conditions (20% cyclic strain) and compare these results to those under physiological (6–
10% cyclic strain) and static conditions. 
 
Specific Aim 2: Determine whether it is possible to use specific inhibitors to 
modulate c-Myc transcriptional activation and, thereby, determine the mechanism 
of c-Myc transcription by cyclic strain   
By using compounds that directly target the silencer element in the c-Myc promoter, it 
will be determined if cyclic strain–induced c-Myc transcription can be attenuated.   
 
Specific Aim 3: Determine both the mRNA and protein expression of downstream 
genes (especially those related to cardiovascular disease), which are regulated by 
c-Myc 
Once establishing that c-Myc transcriptional activation can be attenuated (specific aim 2), 
it will be examined if this modulation can affect the transcription of c-Myc target genes.  
Cyclically-strained endothelial cells will be treated with and without compounds that 
prevent c-Myc transcription in order to examine potential downstream targets (vascular 
endothelial growth factor, proliferating cell nuclear antigen, and heat shock protein 60). 
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The completion of these studies helped to elucidate the genetic expression of 
HUVEC in response to cyclic strain.  Hopefully, these results will contribute to the 
understanding of the link between hemodynamic forces and the physiology of arterial 
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2.1 Arterial Physiology 
  
Research on the structure and function of arteries is imperative to understanding 
the pathophysiology of cardiovascular disease, the primary cause of death in developed 
countries.  Although there exists extensive knowledge in this field, arteries are complex 
and dynamic—arterial cells actively respond to and affect their surrounding mechanical 
and biochemical environments.  This background and literature review offers a 
generalized understanding of arterial physiology, with an emphasis on one specific 




The human artery is composed of three concentric layers surrounding a lumen, 
through which the blood flows.  The layers are the tunica intima, tunica media and the 
tunica adventitia, as idealized in Figure 2.1.   
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The three layers are distinguished by their extracellular matrix and component 
cell type.  They are bound together by connective tissue.  The intima, the innermost layer, 
is in direct contact with the blood.  It consists of a single layer of endothelial cells and 
rests on a connective tissue membrane that is rich in elastic and collagenous fibers.   The 
media makes up the bulk of the arterial wall and is composed primarily of concentric 
layers of elastic laminae interposed with layers of extracellular matrix and contractile 
smooth muscle cells.  The outermost, relatively thin layer, which attaches the artery to the 
surrounding tissues, is the adventitia.  It consists chiefly of connective tissue with 




The overall function of arteries is to deliver blood from the heart to the peripheral 
vessels, but these conduits also play important roles in vascular hemodynamics.  Arteries 
regulate vascular mechanics primarily at the cellular level by controlling vascular tone, 
regulating the vessel diameter and by dampening pulsatile pressure waves [6].   
 
2.1.3 Endothelial  Cell Biology 
 
Endothelial cells line the lumen of all blood vessels, serving as a barrier between 
blood-borne constituents and the underlying vascular tissue.  Their function is 
complicated with multiple roles, including: cell growth, migration and differentiation, 
maintaining vascular tone, and responding to injury.  EC accomplish these diverse tasks 
through cytokines, vasoactive peptides, and growth factors.  Additionally, EC are directly 
exposed to the forces developed from blood flow and pressure.  As a result of this direct 
contact, they are believed to be the primary mediators of response to shear stress and 
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cyclic strain [7, 8].  In fact, EC at sites of complex flow (i.e. vessel bifurcations and 
curvatures) exhibit increased permeability and a proinflammatory phenotype [9].  
Disruptions in the hemodynamic forces imparted on vascular EC can cause their secretion 
of vasoactive factors including vasorelaxants (e.g. nitric oxide and prostacyclin) and 
vasoconstrictors (e.g. endothelin-1 and platelet-activating factor) and in the long-term, 
remodeling of the vessel wall [10].    
 
2.2 Arterial Hemodynamics 
 
The three hemodynamic forces imparted on vascular EC by blood flow are shear 
stress, hydrostatic compression and cyclic (circumferential) strain.  Each of these forces 
has an associated phenotype and gene expression profile.  Additionally, due to inherent 
differences in the varying types of blood vessels, the properties of the vessel wall vary 
along the vascular tree.  Large and medium-sized arteries behave differently than 
capillary vessels, which in turn behave differently than low pressure veins.  Within the 
arteries, typical physiological values of shear stress, cyclic strain, and transmural pressure 
range from 6 to 40 dyne/cm2, 6% to 10% at 1 Hz, and 60 mmHg to 140 mmHg, 
respectively [11].  Although all three forces mediate vascular responses, some evidence 
indicates that shear stress and hydrostatic compression may not be the major factors 
influencing atherosclerosis or other vasculoproliferative cardiovascular diseases [2].  
Rather, cyclic strain, which results from pulsatile blood flow, is the principal factor in the 
localization of these diseases [2].  Cyclic mechanical strain regulates the apoptosis, 
proliferation, and migration of vascular cells, and the degradation, synthesis, and 
reorganization of extracellular matrix [12].  Therefore, for the purpose of this 
dissertation, this review of arterial hemodynamics will emphasize cyclic strain in major, 
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typically elastic arteries, such as the coronary arteries.  In these vessels, normal 
physiological cyclic stain is about 10% [6, 13]. 
The vascular wall exhibits complex material properties, including spatial 
heterogeneity, anisotropy, nonlinearity, and viscoelasticity [6].  Thus, the wall mechanics 
of the native artery are neither simple nor straightforward.  However, by making a few 
assumptions, it is possible to derive a simplified relationship between transmural blood 
pressure and wall stretch. 
Under normal conditions, the arteries are always “pressurized.”  Therefore, based 
upon the law of LaPlace, the wall stress in the circumferential direction for a thin-walled 
cylinder of wall thickness, h, and with transmural pressure, P, can be approximated as 
(inertial effects ignored): 
 
σθ (t) = P * r 
            h 
 
where r is the deformed radius. 
 
 
From Hooke’s law for an elastic, thin-walled cylinder, circumferential strain (εθ) can be 
equated to circumferential (hoop) stress (σθ) through the definition of bulk Young’s 
modulus, E, by the formula: 
 
εθ = (1/E)(σθ) 
 
 
Thus, if the artery is assumed to be a classic pressure, thin-walled, linear elastic cylinder, 
governed by LaPlace’s and Hooke’s laws, a very simple model can be developed to 
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provide a basis for in vitro work.  By equating the stress and strain, the relationship 
between transmural blood pressure and wall stretch is derived: 
 
εθ = σθ/Ε = (P∗r) 
                                                     (h∗E)  
 
Although this simplified equation is only applicable for infinitesimal strains of a 
thin-walled, linear elastic cylinder, it demonstrates that the relative circumferential 
expansion of the arterial wall is directly related to the wall composition and structure.  
Restated, arterial pressure, comprised of both blood pressure and pulsatile tensile stresses, 
causes a radial-directed stress in the wall, and the resulting strain directly depends on the 













Figure 2.2: Mechanical forces acting on the artery 
The figure at right shows the resultant stresses acting on an element of the vascular wall, 
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2.3 Vascular Obstructive Diseases 
 
Through autocrine and paracrine hormonal mechanisms, EC are able to react to 
local hemodynamic modifications.  Almost immediately, vascular tone is used to 
compensate and restore any changes in mechanical forces.   As reviewed in Section 2.1.3, 
one of the functions of EC is to respond to humoral agents and injury.  If the endothelium 
is damaged, dysfunction is clinically characterized by a loss of nitric oxide production 
and therefore, reduced endothelium-dependent vasodilation.  The shift in phenotype to a 
state of dysfunction is also characterized by increases in endothelial adhesiveness, 
permeability, proliferation, and thrombogenesis.   
When the phenotype of vascular cells is altered or compromised, and thus not 
capable of restoring physiological levels through vascular tone alone, vascular 
remodeling occurs and can lead to vasculoproliferative diseases.  These disorders can 
occur as a result of numerous pathological conditions, notably atherosclerosis, 
hypertension, and the consequence of mechanical interventions.  The pathologies are 
similar in that they result in an abnormal narrowing of the blood vessel.  Advanced lesion 
formation can result in mortality or serious tissue damage, including cerebral and 




Atherosclerosis is the pathological event leading to the development of plaque on 
the inner walls of arteries, decreasing lumen size.  Specifically, vascular injury triggers a 
vasculoproliferative cascade that can be divided into three phases: (1) an early phase of 
platelet activation and thrombus formation, (2) an intermediate phase of vascular smooth 
muscle cell (VSMC) recruitment, and (3) a late proliferative phase [14].  It is known that 
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hemodynamics and the endothelium mediate these atherosclerotic events, but the balance 




 Hypertension is an increase in blood pressure due to a narrowing lumen and 
reduction in vessel elasticity.  Instead of being focal in nature, like atherosclerosis, 
hypertension involves diffuse changes in hemodynamics and arterial structure.  
According to one hypothesis, high blood pressure causes chronic damage to the 
endothelium, promoting plaque formation [5].  Therefore, although not a “disease” by 
definition, chronic hypertension can lead to vessel stiffness via extracellular matrix 
(ECM) deposition, hypertrophy and hyperplasia of VSMC in the intima and media.   
 
2.3.3 Surgical Intervention 
 
In an effort to reduce CVD mortality, a variety of procedures, including balloon 
angioplasty, endarterectomy, and coronary artery bypass grafting and stenting, are 
performed.  In 2004, an estimated 6,363,000 inpatient cardiovascular operations and 
procedures were performed in the United States, contributing to a decline in CVD 
mortality [1].  However, these treatments, like atherosclerosis, involve acute mechanical 
injury to the structure of the vessel wall, leading to increased susceptibility to 
atherosclerosis, aneurysm formation, and plaque disruption.  Remodeling of the injured 
vasculature usually occurs within a few hours or days after injury [15] and often leads to 
neointimal hyperplasia and eventually, restenosis.  It is estimated that 30 to 50% of 
patients undergoing percutaneous coronary interventions will experience restenosis [16, 
17], and 20% of these will require additional operations, including coronary artery bypass 
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surgery, a procedure that in itself is limited by graft failure due to luminal obstruction 
[18].  Estimated costs as a result of restenosis complications exceed $3.5 billion per year 
in the United States alone [19]. 
 
2.4 Treatment of Vasculoproliferative Disease 
 
 
2.4.1 Improved Stent Design  
 
Stenting serves to unblock and hold open a narrowed vessel, ensuring perfusion to 
downstream tissue.  Since it is a less caustic method than radiation or brachytherapy, 
stenting is a popular method to treat vasculoproliferative diseases.  Recent reports state 
that more than 1.25 million stents are implanted in North America annually [20].  
However, the consequences of stent placement are often deendothelialization, dissection 
of the media and occasionally the adventitia, and stretch of the entire artery [21].  In 
addition, a complex interaction occurs between the blood and the biomaterial surface.  
The complement system is activated, platelets and leukocytes become activated, and 
coagulation leads to thrombi formation [22].  These events initiate the arterial wall’s 
healing response to mechanical injury, often leading to restenosis. 
 
2.4.1.1 Drug-Eluting Stents (DES) 
 
Since restenosis after stent placement is entirely the result of intimal hyperplasia, 
stent coatings with drugs or non-pharmaceutical agents may reduce in-stent restenosis.  
The metal stent is either coated with a matrix, allowing controlled drug release, or the 
pharmacological agent is incorporated into a polymer-metal composite stent [23].  Thus 
far, in comparison to bare metal stents (BMS), these “drug-eluting stents (DES)” have 
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been successful in reducing restenosis (from the 20–30% range to single digits [24]) and 
neointimal hyperplasia [25]. 
It is important to consider the local drug pharmacokinetics when designing a 
DES.  Any pharmacological agent delivered locally is influenced by the local transport 
forces, which are related to the properties of the target tissue.  Suboptimal transport could 
result in either toxic or nontherapeutic levels.  The highly heterogeneous composition of 
the arterial wall and its asymmetric geometrical organization represent a challenge for 
most agents applied in DES technologies [21].  The ideal compound should contain 
hydrophobic elements to ensure high local concentrations as well as hydrophilic 
properties to allow homogeneous drug diffusion. 
DES also have potentially dangerous complications.  Recent studies report 
increased risk of stent thrombosis, myocardial infarction, and death associated with the 
use of this type of stent [26-28].  Since the currently employed drugs fail to specifically 
target the factors involved in the vascular injury caused by surgical implantation, there 
are complications known as "late stent thrombosis."  The antiproliferative agents prevent 
the growth of endothelial cells onto the stent, thereby increasing the tendency for blood 
clotting inside the stent.  This complication is generally avoided in BMS because they 
promote the growth of a smooth, thin layer of endothelial cells, incorporating the device 
into the artery [29].  A possible solution could be designing a drug-eluting stent which 
employs a novel drug designed with a molecular-target approach, specifically targeting 
the factors involved in vascular injury.   
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2.4.1.2 Alternative Stent Improvements 
 
The alternative approach to improving stent design acts to accelerate, not inhibit, 
the healing process.  Healing-enhancing stents aim to reduce VSMC migration and 
proliferation, promote local angiogenesis, and improve re-endothelization.  These stents 
are coated with growth factors, hormones or antibodies [30] to prevent endothelial 
denudation and subsequent thrombosis.  For example, researchers have designed a stent 
coated with anti-human CD34 antibodies in order to capture circulating endothelial 
progenitor cells [31].  The estrogen-releasing stent [32], the nitric-oxide-releasing stent 
[33], and the cell migration inhibitor (batimastat)-releasing stent [34] use elution to 
control inflammation and accelerate endothelial regeneration.  Animal studies from these 
novel stents ascertain that this new technology may be an effective means to treat 
restenosis.  However clinical trials are still underway and future investigations are 
necessary to overcome methodological limitations, such as dosing and vehicle delivery. 
 
2.4.2 Intraluminal Radiotherapy 
 
Intraluminal radiotherapy of arteries has been shown to inhibit restenosis by 
suppressing neointimal growth.  The irradiation can target cells in all three layers of the 
blood vessel, i.e. from the intima to the adventitia.  This technology attempts to inhibit 
new cell growth without causing long-term vascular necrosis.  Several irradiation 
techniques are currently being investigated, including temporary intravascular insertion 
of gamma or beta-emitting wires, inflating balloon catheters with radioactive liquid, and 
using radioactive impregnated stents.  However, uncertainties in dose-volume effects and 
the biological time course of restenosis make intraluminal radiotherapy as yet difficult to 
both plan and execute [35]. 
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2.4.3 Gene Therapy 
 
Since in-stent restenosis remains an important clinical problem, gene therapy 
offers an alternative approach for treating vessel remodeling.  The genes delivered to 
vascular wall cells can encode for proteins that are either directly or indirectly cytotoxic 
or cell cycle-inhibitory.  There is great interest in developing a strategy for safe, efficient, 
targeted gene delivery into the vessel wall.  However, as a result of the nature of 
atherosclerotic lesions and lipid-rich atheroma, there is a potential for harmful 
biodistribution of vector.   
Under evaluation are several approaches using gene therapy to prevent or reduce 
intimal hyperplasia.  Viral vectors have the advantage of high gene transfer efficiency 
[36], but their success has limitations.  Adenoviruses efficiently transfect both 
proliferating and quiescent cells, but they often have a short duration of expression and 
transfect untargeted organs and cells [37].  Retroviruses, lentiviruses, and baculoviruses 
are limited by host reactions and safety concerns.  An attractive alternative approach is 
plasmid DNA with or without carrier molecules, because it is easy to produce and has a 
high level of safety.  However, it is limited by low efficiency of gene transfer in vascular 
applications [37]. 
In spite of recent promise in the field of gene therapy, including success in 
preclinical animal models [38], there are not yet any therapeutic effects in clinical trials 
[39, 40].  Additionally, gene therapy is best suited for treating genetic disorders with 
single gene defects [36] and therefore, is unlikely to be successful in treating most 
vascular obstructive diseases, which involve multiple genes.  Thus, this CVD treatment 
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option faces the same problem as the DES and radiotherapy fields—a need to develop an 
optimally-targeted pharmacological solution. 
 
2.5 Role of c-Myc in Vascular Disorders  
 
Cardiovascular disease and cancer are the predominant causes of mortality in 
industrialized countries [41].  Biological evidence suggests that these human pathologies 
may share pathological mechanisms.  The three stages of carcinogenesis—induction, 
growth and invasion of tissue, and neoangiogenesis—parallel the course of 
atherosclerosis—initiation, progression, and complication.  As a result of these 
commonalities, genes that have classically been studied in regards to carcinogenesis 
(c-Myc, Ras, and the Insulin-like growth factor-1 cascade) are now being linked to 
endothelial dysfunction and atherogenesis [42]. 
Specifically, a growing body of evidence implicates that the c-Myc proto-
oncogene can play a pivotal role in cardiovascular disease.  c-Myc, whose overexpression 
is associated with a significant number of human cancers [43, 44], controls numerous 
functions, including cell cycle progression, differentiation, and apoptosis [45-47].  In fact, 
c-Myc expression occurs within 30 minutes of mitogenic stimulation of quiescent cells, 
and peaks around 2 hours [48].  Disruption of c-Myc gene expression lengthens both the 
G1 phase of the cell cycle (prior to DNA synthesis) and the Go to G1 transition [49, 50].  
Moreover, c-Myc plays a key role in p27 sequestration through modulation of the level of 
regulatory cyclin D and E proteins [51]. 
Specific to the development of obstructive vascular disease, c-Myc is quickly 
induced in VSMC after arterial injury [50] and activated by proliferative signals, 
including a number of mediators of vascular EC biology, such as LDL [52], thrombin 
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[53], endothelin [54], and angiotensin II [55].  Inhibition of c-Myc has been shown to 
inhibit smooth muscle cell proliferation in vitro and in several animal models [56].  
Several studies suggest that c-Myc may be involved in the regulation of angiogenesis 
[57].  Research with c-Myc knockout mice indicates that a deficiency in this gene causes 
serious defects in the development of blood vessels, angiogenesis and erythropoiesis [58, 
59].  c-Myc also regulates the downstream genes causing cell migration and adhesion, 
collagen formation, secretion of extracellular matrix, and cell proliferation [60].  When 
compared with healthy conditions, there is increased c-Myc expression in atherosclerotic 
plaques, after carotid injury, and in hypertensive rats [61]. 
 
2.5.1 Targeting of c-Myc to Treat Vascular Diseases 
 
To combat atherosclerosis and other cardiovascular diseases effectively, drugs are 
needed to downregulate the overexpressed genes comprising the vasculoproliferative 
response.  Transcriptional factors such as c-Myc, which are downstream of the signaling 
cascades, have advantages because, unlike targeting a signaling molecule, there is less 
likely to be redundancy due to upregulation of parallel pathways, resulting in drug 
resistance.   
Additionally, since c-Myc is an early-activated oncogene, a drug regulating its 
expression would only need to be released in the first 48 hours following intervention.  In 
fact, in vivo studies have shown that single-dose suppression of c-Myc can prevent 
neointimal formation months later because the proliferation is critically dependent upon 
mitogenic events that occur very shortly after injury [62].  Not only does this treatment 
generate an easily controllable local pharmacokinetic profile, but it also has enormous 
potential for drug-eluting stents [63].  After the relatively brief delivery of the anti-
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restenosis drug, the stent would become a bare metal stent—which may eliminate the 
concern of late stent thrombosis present in currently-designed drug-eluting stents.  With 
bare metal stents, endothelial cells are able to grow, incorporating the device into the 
artery.  A major complication of drug-eluting stents in use today is that the drugs that 
coat them have a long-term potency that prevents regrowth of endothelium, increasing 
the risk of thrombosis months later. 
For all of these reasons, inhibition of c-Myc-dependent signaling has become a 
novel therapeutic opportunity in vascular obstructive diseases.  Strategies have been 
undertaken to downregulate c-Myc, such as through intervention with antioxidants, RNA 
synthesis inhibitors, and antisense oligonucleotides against c-Myc [64].  However, an 
effective means to modulate c-Myc gene expression in humans has yet to be developed.   
 
2.5.1.1 Antisense Oligonucleotides  
 
The mechanism by which antisense oligonucleotides (AS OND), the most-
researched therapy, inhibit expression of c-Myc involves interference with translation of 
the target c-Myc mRNA [65].  Thus far, these strategies have shown prevention of 
restenosis in animal models [66].  In rat studies, c-Myc AS OND reduce negative 
remodeling induced by arteriotomy, significantly reducing cell proliferation, 
inflammatory cell infiltration, and medial oedema [50].  However, when c-Myc AS OND 
were studied in humans, there was no reduction in angiographic or clinical restenosis 
after bare metal stenting [39] or in randomized human clinical trials [56].  It is generally 
believed that the ineffectiveness of these therapies in humans is due to an inherent 
nonspecificity, a slow uptake across the cell membrane, and rapid intracellular 
degradation of the oligonucleotide [67].  AS OND have unfavorable pharmacokinetics 
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because a significant fraction of antisense may be retained by membrane lipids [63] and 
large amounts of drug are required to produce an effect.  
Instead, what is needed to effectively treat these vascular obstructive diseases is a 
de novo drug design.  A novel and potentially more effective drug would prevent c-Myc 
transcription (and therefore downstream gene expression) by directly targeting the c-Myc 
silencer element.   
 
2.5.1.2 Drug Targeting: Arizona Cancer Center Collaboration 
 
Since there is an established relationship between vasculoproliferative 
cardiovascular diseases and cancer, a logical next step would be the investigational 
application of cancer drug therapies in the cardiovascular field.  c-Myc has been a 
particularly attractive target for cancer drug development because it is overexpressed in 
the majority of tumor types and its inactivation can induce regression of malignant 
cancers.  The University of Arizona Cancer Center (UAZCC) in Tucson, Arizona actively 
researches and develops cell-selective molecular targets for antitumor application, 
specifically identifying compounds targeted to the c-Myc promoter.  Their drug design 
involves the traditional approach of using a small molecule as the starting point for drug 
optimization.  
c-Myc transcription takes place when transcription factors heterogeneous nuclear 
ribonucleoprotein (hnRNP K) and cellular nucleic acid binding protein (CNBP) bind the 
c-Myc promoter.  The compounds identified by UAZCC are able to silence the c-Myc 
promoter and thus, repress gene expression by preventing this binding of hnRNP K and 
CNBP to the c-Myc promoter.  As proof of principle, the Cancer Center has performed 
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chromatin immunoprecipitation (ChIP) analysis.  In unpublished data, their results verify 
that these compounds almost completely inhibit hnRNP K and CNBP binding. 
  As justification of the modulation capability of these compounds, UAZCC has 
performed serum-starvation experiments.  It is well established that serum induces c-Myc 
expression in numerous cell types.  In order to monitor basal levels of c-Myc, cells are 
often serum-starved, thus inducing a quiescent growth state.  In a serum-starvation study 
with cancer (HeLa) cells, UAZCC researchers showed that compounds prevent the 
recovery of c-Myc levels after starvation.  HeLa cells were grown to confluence, then 
rinsed and placed in media without serum for 12 hours.  After serum-starvation, cells 
were then given media containing serum with and without drug.  After starvation, c-Myc 
mRNA expression levels are about 0.4.  When serum is added back to the cells and no 
drug is given, c-Myc levels increase to 0.75.  On the contrary, when cells are given serum 
AND drug, there are no noticeable differences from serum-starved cells—the levels 
remain around 0.4.  Therefore, these findings indicate that University of Arizona has 
identified drugs that are able to modulate the transcriptional activation of c-Myc. 
Thus far, these UAZCC compounds have only been studied in oncology, but there 
is also a clear application in cardiology.  Additionally, these compounds have both 
hydrophobic and hydrophilic properties—desirable traits for allowing homogeneous drug 
diffusion on a DES. 
Therefore, a Material Transfer Agreement has been established between 
University of Arizona and Georgia Institute of Technology.  This project utilized 
University of Arizona’s lead compounds to investigate the modulation of c-Myc 
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transcriptional activation in my own experimental setup, which mimics the hemodynamic 
conditions associated with vessel remodeling and atherosclerosis. 
 
2.5.2 Structure of c-Myc Promoter Region 
 
The c-Myc gene is located on human chromosome 8q24 and consists of three 
exons.  Translation at the AUG start site in the second exon produces a major 439 amino 
acid, 64 kDa c-Myc protein  [68].  The transcriptional regulation of c-Myc expression is 
complex and involves multiple promoters and transcriptional start sites.  The nuclease 
hypersensitivity element (NHE III1) in the c-Myc promoter controls up to 90% of the 
transcriptional activity of this gene that occurs at the P1 and P2 promoters (the 









The NHE III1 sequence includes an inordinate number of guanine residues on one 
strand and the corresponding cytosine residues on the opposing strand.  The unique 
G-rich and C-rich sequences impart a special property to the DNA in this region—the 
ability of this duplex NHE III1 to convert to a structure in which the purine-rich strand 
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adopts a G-quadruplex structure [71-73] (Figure 2.4).  When NHE III1 takes on this form, 
either side of these structures is single-stranded for at least one turn on each side.  By 
stabilizing this silenced form, the binding proteins hnRNP K and CNBP, which directly 
mediate transcriptional activation, can be prevented from binding.  In other words, by 
transforming the purine-rich sequence of the NHE III1 to a parallel G-quadruplex 
structure, hnRNP K and CNBP cannot bind.  Thus, gene expression is silenced [74].  
Potential drugs could succeed in preventing transcription of c-Myc by stabilizing this 









2.6 Genetic Markers of Vasculoproliferative Diseases 
 
Direct targets of c-Myc are defined as genes whose expression is directly 
regulated by binding of the c-Myc protein to the promoter region.  These target genes 
have been identified by several techniques including DNA microarray analysis and serial 
analysis of gene expression (SAGE).  It is important to point out that there may be 
differences in the c-Myc targets induced in normal cell homeostasis and those induced in 
pathophysiological conditions when c-Myc is overexpressed.  The following are potential 
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downstream targets of c-Myc that have also been implicated in promoting 
vasculoproliferative diseases. 
 
2.6.1 Proliferating Cell Nuclear Antigen (PCNA) 
 
Proliferating cell nuclear antigen (PCNA) has been identified by microarray as a 
transcriptional target of c-Myc (3.2–fold upregulation) in rat endothelial cells [75].   This 
protein was originally identified as an antigen expressed in cell nuclei during the DNA 
synthesis phase of the cell cycle.  PCNA encircles double-stranded DNA as a trimer, 
forming a sliding clamp that tethers proteins such as polymerases to DNA [76].  Based 
upon its essential role in DNA synthesis and therefore, increased concentrations during 
the cell cycle, this protein is considered to be a valid indicator of cell replication.  Cells 
traversing the cell cycle are often identified by PCNA immunostaining. 
PCNA is implicated as a downstream gene of c-Myc [77] and in relation to CVD, 
PCNA has been identified as playing an important role in vascular remodeling 
(proliferation, migration, and phenotypic change).  Its expression is frequently used to 
determine the proliferation activity of endothelial cells in restenotic tissue [78] and matrix 
accumulation in neointimal vasculature [79] obtained from porcine coronary angioplasty.  
Smooth muscle cell proliferation, an important stage in the pathogenesis of vascular 
obstructive diseases, can be inhibited in vitro and in several animal models by inhibiting 
PCNA expression [56].  Because of its role in vascular disease, in addition to targeting 
the c-Myc gene for AS OND, research is also directed towards developing AS OND for 
PCNA [80]. 
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2.6.2 Heat Shock Protein 60 (HSP60) 
 
HSP60, a protein which is expressed on the endothelial surface, has been 
identified as a transcriptional target of c-Myc [81] through SAGE and confirmed with 
microarray (5-fold induction).  It is a suspected contributor to the initiation and 
aggravation of vascular pathologies like atherosclerosis and restenosis [82].  The first 
published discovery of human HSP60 detection in diseased vascular tissue was in the 
early 1990s [83], with the identification of HSP60 expression in atherosclerotic lesions.  
Subsequent research has validated this discovery, showing localization of HSP60 in 
neointimal, but not healthy, vasculature [84] and soluble HSP60 levels associated with 
intima–media thickness [85]. 
With increasing studies, HSP60 is now being recognized as a marker for early 
cardiovascular disease.  Elevated HSP60 levels have been identified in patients with 
borderline hypertension and there is an association between early atherosclerosis and 
HSP60 levels [86].  Further, HSP60 both activates and is induced in endothelial cells, 
smooth muscle cells, and monocyte-derived macrophages in atherosclerotic lesions [85].  
Endogenous as well as exogenous HSP60 have been implicated in stimulating vascular 
smooth muscle cell proliferation in a concentration-dependent fashion [87, 88]. 
The association of HSP60 with the induction/progression of both chronic 
hypertension and atherosclerosis can be further substantiated from a vascular mechanics 
point of view.  Disturbed flow patterns have been found to induce HSP60 and have been 
suspected to provoke autoimmune reactions which result in atherogenesis [89].  Altered 
hemodynamic conditions, like those found in venous bypass grafts and atherosclerosis-
prone sites of the vascular tree, are also possible causes of HSP60 induction.  In 
   
25 
particular, increased levels of fluid shear stress (30 dynes/cm2) increased HSP60 
expression in endothelial cells in vitro [81, 90].   
 
2.6.3 Vascular Endothelial Growth Factor (VEGF) 
 
Vascular endothelial growth factor (VEGF)  is well characterized as a 
transcriptional target of c-Myc at both the mRNA and protein levels [91].  In fact, 
upregulation of c-Myc has been shown to cause almost a 10-fold induction of VEGF 
expression [92].  Within the vasculature, VEGF is a potent mitogen, identified as a 
mediator of c-Myc–induced angiogenesis. 
VEGF plays a key role in both physiological and pathological conditions.  This 
growth factor is involved in processes ranging from wound healing and 
neovascularization to carcinogenesis and cardiovascular disease [36].  It acts on 
endothelial cells, inducing various effects, including increased vascular permeability, 
angiogenesis, vasculogenesis, and endothelial cell proliferation and migration [37].  
Although VEGF is necessary for maintaining hemostasis, studies also indicate 
that increased expression and activity of endogenous VEGF are essential to the 
development of restenosis.  Injurious conditions due to pathologies or surgery alter the 
mechanical environment, leading to a thickening and subsequent increased stretch of the 
vessel wall.  In VSMC, the increasing stretch induces a significant increase in VEGF 
expression both at the mRNA and protein levels [93] and in a time- and amplitude-
dependent manner [94].  Since VEGF enhances neointimal formation and atherogenesis 
in vitro and in vivo [21], these findings suggest that VEGF plays a role in arterial disease.  
In fact, higher levels of VEGF are found in atherosclerotic and restenotic legions as 
compared with normal, healthy tissue [95, 96].   
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2.7 Cell Culture Models of Mechanical Forces  
 
The fluid mechanical forces imparted by blood flow have been implicated in 
playing a pivotal role in the initiation and progression of CVD.  Stenotic lesions 
preferentially develop in regions of disturbed blood flow, implicating that local 
hemodynamic forces directly influence pathobiological processes.  Endothelial cells 
grown statically on tissue culture fail as an appropriate in vivo model of EC behavior 
because this oversimplified system lacks the critical feature of mechanical stress.  In vivo, 
EC experience stress from the flow of blood, pressure fluctuations, and pulsatile stretch 
(see Section 2.1.3).  Relevant to this dissertation, c-Myc has been reported to respond not 
only to shear stress, but also to other types of mechanical forces, such as pressure 
overload and stretch in cardiac myocytes [97]. 
At present, however, it is not possible to monitor and control the hemodynamic 
factors in the vicinity of the vessel wall.  Since an in vivo model does not exist, the 
mechanism by which mechanical forces modulate the morphology, metabolism and 
genetic expression of EC must be studied with appropriate in vitro models.  Various types 
of experimental apparatuses have been developed to impose different forms of 
mechanical forces on culture cells.  Thus far, limited studies have been performed using 
direct hydrostatic pressure separate from circumferential wall tension. 
 
2.7.1 Shear Stress Models 
 
In order to mimic the effect of arterial wall shear stress due to blood flow, in vitro 
models study fluid flows on cultures.  These designs usually involve a parallel plate, cone 
and plate, or flow loop apparatus.  Published research studying the gene expression 
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effects of shear stress indicate that flow induces c-Myc expression, peaking in the 1.5–2 
hour time range.  Specifically, Li et al. found that both steady and 1 Hz pulsatile flow 
(average shear stress of 16 dynes/cm2) caused slight increases in c-Myc mRNA levels 
which peaked at 2 hours and returned to basal levels by 4 hours [98].  Hsieh et al. 
investigated c-Myc protein levels in HUVEC subjected to steady shear stress at very low 
levels (4 and 10 dynes/cm2).  Their results show a peak in expression at 1.5 hours, which 
falls to basal levels by 2.5 hours [99].  Both of these studies substantiate the role of 
c-Myc expression in the pathogenesis of vascular disease. 
 
2.7.2 Cyclic Strain Models 
 
 Although several types of devices have been used to induce mechanical stretch  
in vitro, in general, researchers have employed two different stretch regiments to mimic 
pulsatile circumferential wall stretch: uniaxial and biaxial.  Different types of mechanical 
stretch elicit different molecular and cellular responses.  Uniaxial systems mimic in vivo 
pulsatile (one-dimensional) expansion of the artery wall.  Biaxial systems are 
advantageous because multiple systems can be run in parallel, but they incur a non-
uniform strain field and are therefore inconsistent with in vivo mechanics. 
In the biaxial stretch apparatus, cells are generally cultured on a circular 
membrane, constrained at the periphery.  Cyclic stretching is imposed either by vacuum 
suction of the air or fluid below the membrane or by moving a central piston.  The strain 
field produced is non-uniform throughout the membrane—maximal strain occurs near the 
outer edges, where the strain is primary radial as a result of clamping.   Approaching the 
membrane center, strain levels decrease and the strain field is isotropic and biaxial.  At 
the center, strain is close to 0%.  A commercially available system called “Flexercell” 
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utilizes a vacuum-operated biaxial system.  Extensive studies reveal that the biaxial strain 
induced in this system are insufficient to model vascular cyclic strain and in fact, are 
more appropriate for studying heart tissue and bone mechanics, where biaxial strain is 
apparent in vivo [100-102].  Additionally, during stretching, microscopic observation is 
impaired as a result of vertical movement in the center of the membrane.   
Another model for cyclic strain implements an equibiaxial system.  Indenter 
devices apply a uniform and equibiaxial strain to the membrane, but they have a limited 
range of cyclic strain (0.04–0.4%).  These low percentages are suitable for bone cells, but 
not for vascular applications [103].  In one equibiaxial strain model [104], research found 
that endothelial cells were exposed to the same stress field and showed no morphological 
changes after 20% cyclic strain at 1 Hz.   Since in vivo morphology indicates that cells 
orient themselves perpendicular to circumferential stretch, this lack of cytoskeletal 
reorganization makes results suspicious for in vivo application. 
In uniaxial stretching devices, such as employed in this dissertation, the cells are 
cultured on a rectangular membrane, with one end anchored and the other end pulled at a 
certain frequency.  Since the membrane in these devices moves only in one direction, 
microscopic observation of the cultured cells is relatively simple. Additionally, consistent 
with in vivo observations, morphological studies show that endothelial cells subjected to 
uniaxial cyclic strain orient themselves so that their long axis is perpendicular to the 
direction of stretch.  This reorganization may play a fundamental role in regulating 
vascular tone and blood fluidity.  Theories on cell alignment conjecture that the 
perpendicular alignment may be an attempt to reduce the strain energy exerted on the cell 
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[105].  Cells may be trying to minimize stretching of microtubules or other cytoskeletal 
networks during pulsation.  
Published studies measuring c-Myc expression levels in cyclic strain models are 
limited.  Thus far, no one has reported on the effect of c-Myc gene expression in uniaxial 
stretched HUVEC.  However, preliminary research has investigated the effect of 20% 
uniaxial stretching of cardiac myocytes [106].  This group reported a transient stretch–
induced upregulation of c-Myc mRNA that peaked around one hour.  
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3.1 Experimental Procedures 
 
3.1.1 Cyclic Strain Model 
 
 The system was designed to mimic the “normal” in vivo conditions that arteries 
experience during circumferential expansion.  Since the radius of curvature of large 
arteries is much greater than the dimensions of the cell, the in vitro design was simplified 
by “cutting” a vessel along its axis and laying it flat, as shown in Figure 3.1.  In this way, 
fluid shear stress and wall strain act together to cause alignment of the EC parallel to the 
flow axis of the vessel.  In short, cyclic strain is imposed by culturing EC on a flexible 
membrane that is inserted into a chamber with one side of the chamber oscillating. To 
mimic the heart beating, a simple sinusoidal function (uniaxial cyclic strain) was imposed 






Figure 3.2: Rationale for cyclic strain model 
In Vivo In Vitro 
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3.1.1.1 Elastic Substrate 
 
Silicone sheeting (Specialty Manufacturing Inc) was chosen as the substrate 
material because it is elastic, relatively inexpensive, readily available, non-toxic, and 
chemically inert.  It is also optically clear, allowing for microscopic visualization of the 
cells. Another advantage of the silicone is that it does not lose its elasticity with 
autoclaving sterilization and can be stored at this stage for several weeks.  The elastic 
substrate was cut to 8 centimeters long x 4 centimeters wide, a uniform geometry that 
provides uniform strain with axial loading.  Since the membrane is very thin (0.005 
inches), relative to its width and length, edge effects on the strain distribution are 
minimized (St. Venant’s principle) [107]. 
 After cutting membranes, they were placed in sealed autoclaving bags and 
sterilized for 10 minutes at 135°C.  At the time of cell seeding, autoclaved membranes 
were moved to a laminar hood and assembled into the cyclic strain chamber.  The 
detailed procedure is given in Section 3.1.1.3 
 
3.1.1.2 Surface Modifications of Silicone Membrane 
 
Although the silicone is medical implant grade and therefore biocompatible, its 
main disadvantage is its hydrophobic nature which prevents cell attachment.  In order to 
improve this property, the silicone surface was modified through gelatin and 
gluteraldehyde cross-linking.  Biological candidates for extracellular matrix include 
structural proteins (i.e. collagen and elastin), adhesive proteins (i.e. fibronectin and 
laminin), and polysaccharide glycosaminoglycans (i.e. heparin and hyaluronic acid).  
Cells will secrete their own ECM after attachment, but it is important to select an 
artificial matrix that will encourage this process.   
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For the purposes of these cyclic strain experiments, gelatin (Sigma) was chosen as 
an appropriate substrate for growing a confluent monolayer and retaining attachment, 
even during stretching.  Once the stretch chambers were assembled, 1% gelatin dissolved 
in 1x phosphate buffered solution (PBS) was added to the membranes and the entire 
chamber was incubated at 37°C for at least one hour. 
In order to crosslink the gelatin to the membrane, 0.5% (final concentration) 
gluteraldehyde [108] was added to the gelatin and the membranes were incubated at room 
temperature for 25 minutes.  Immediately following, since residual gluteraldehyde is very 
toxic to cells, the membranes were thoroughly rinsed with 1 x PBS.  The PBS wash was 
repeated a minimum of 4 times. 
 
3.1.1.3 Cyclic Strain Apparatus 
 
The apparatus for stretching consists of a polycarbonate chamber divided into two 
identical compartments.  Polycarbonate is non-toxic, sterilizable and optically clear, 
allowing for visualization of the culture before and after stretching. All polycarbonate 
and stainless steel (ss) parts were rinsed thoroughly with deionized water, dried, and 
autoclaved unassembled.  Chambers were assembled under sterile conditions in a laminar 
flow hood.  The silicone membrane is mounted with ss clamps at either end of the 
chamber so that it is positioned close (within 1mm) and parallel to the floor of the 
chamber.  This dynamic model takes into account the effect of not just cyclic strain, but 
also fluid agitation by including a “motion control.”   
Specifically, ss plates were fastened to the rear of the unit and were connected to ss bars 
at the front of the unit.  The bars were set into the arm of the camshaft whose 
displacement was regulated through an adjustable pin mounted atop a rotating cylinder.  
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Displacement frequency is regulated by a DC motor.  A detailed description of the strain 





Figure 3.3: Cyclic strain model 
Cyclic strain apparatus A: relaxed position. B: stretched position.  Upper chamber in both 
A and B contains the cyclically-strained (CS) membrane, whereas bottom chamber 
contains the motion control (MC) membrane [109]. 
Cell Seeding 
Area Metal Frame 
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3.1.2 Human Endothelial Cell Culture 
 
Pooled HUVEC obtained from Cambrex were grown to confluence on pre-
gelatin-coated tissue culture flasks in media [composed of Media-199 supplemented with 
20% fetal bovine serum (Cellgro), 25 mg/mL purified endothelial mitogen (Biomedical 
Technologies), 2 mM L-glutamine (Cellgro), 2.5 U/mL heparin sodium (American 
Pharmaceutical Partners), 50 U/mL penicillin (Cellgro), and 50 mg/mL streptomycin 
(Cellgro)] and maintained at 37°C in the presence of humidified 5% CO2/95% air.  Pre-
warmed (to 37°C) media was replaced every 2–3 days, thus removing metabolic wastes 
and supplying fresh nutrients.  HUVEC growth was monitored by assessing culture 
confluence and the cells were generally passaged every 4–6 days, just prior to reaching 
over-confluence.  Cells were passaged by washing with 1xPBS and then incubating with 
0.25% trypsin-EDTA solution (Gibco), centrifuged, and resuspended in complete 
HUVEC media.  Cells were only used up to passage 5 since stretch-induced gene 
expression has been found to change in late passage EC [97]. 
The same HUVEC lot was used for each independent experiment to minimize 
lot-to-lot variability.  Time-matched static controls were maintained for each stretching 
condition. The cell suspensions (approximately 1 x 106 cells in 1 ml of media) were 
carefully placed onto the pre-treated membranes and allowed at least 4 hours in the 
incubator for attachment.  Cells were uniformly seeded and confluent.  Although many 
cells remained unattached, the entire wetted surface was completely covered, and the cell 
appearance was the typical HUVEC cobblestone morphology characteristic of tissue 
culture.  After cell attachment, 13 ml of complete media were added to each compartment 
and the chamber was placed in the incubator. 
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In order to synchronize the cells, they were incubated in quiescent media for 12 
hours prior to stretching.  This step also removed the unattached HUVEC.  Quiescent 
media is identical to normal media, except it has a low serum content (5% versus 20%) 
and does not contain endothelial growth factor or heparin.  Cyclic strain experiments 
were performed in quiescent media. 
 
3.1.3 Exposure to Cyclic Strain 
 
 During an experiment, the polycarbonate unit was transferred to the motor-gear 
assembly inside a 37°C incubator and in the presence of humidified 5% CO2/95% air.  If 
necessary, the central shaft was coated with antibiotic ointment to provide lubrication and 
minimize contaminate entry via the drive shaft surface.  The motor assembly was plugged 
into an extension cord which was specifically routed into the culture incubator and turned 
on.  The motor speed and cam eccentricity were adjusted to subject the experimental 
membrane to cyclic deformation of 5–20% of its unstretched length at 1 Hz.  The 
movement of the clamp in the motion control (MC) compartment was set to give the 
same media movement as in the experimental cyclic strain (CS) compartment.  Thus, 
although the membrane was not stretched in the MC chamber, fluid motion due to clamp 
motion was nearly identical in both chambers.  In the CS chamber, the movement of the 
clamp provided a cyclic stretching and relaxation of the membrane together with viscous 
drag-induced movement of the media bathing the membrane. An additional control 
utilized cells cultured on membranes maintained under static incubation without any fluid 
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3.2 Experimental Assays 
 
 
3.2.1 Quantitative RT-PCR 
 
 
3.2.1.1 Isolation of mRNA 
 
Immediately after stretch and, if applicable, drug exposure, membranes were 
removed from the cyclic strain chambers under a laminar hood and placed in a sterile 
Petri dish.  The stainless steel clamps were cut off at the point of attachment with a sterile 
scalpel blade.  The HUVEC were washed with ice-cold 1x PBS.  Cells were removed 
from the membrane with a sterile cell scraper and collected in fresh 1x PBS.  The 
resulting cell suspension was centrifuged for 10 minutes at 1500 rpm, 4°C.  After 
aspirating the PBS from the resultant pellet, cells were lysed in Buffer RLT from the 
RNeasy RNA Mini Extraction kit (Qiagen) and homogenized using a QIAShredder 
(Qiagen).  To prevent DNA contamination, on-column DNase digestion was performed 
using RNase-free DNase and Buffer RDD (Qiagen).  The DNase was efficiently washed 
away in subsequent steps.   
The integrity and quantity of RNA was verified through spectroscopic analysis, 
except with very small yields of RNA, which cannot be accurately quantified 
photometrically.  In these cases, RNA was instead quantified by quantitative real time 
polymerase chain reaction (qRT-PCR).  Readings were taken at ultraviolet wavelengths 
of 260, 280, and 320.  The A260/A280 ratio, an indication of RNA purity, was at least 
1.8 for all isolations.  The A320 reading was used to provide a background reading.  The 
A260 reading provided a measure of the concentration of RNA, such that 1 absorbency 
   
37 
unit equaled 40µg of RNA/ml of solution [110].  Purified RNA was stored at -80°C in 
RNase-free water, but used within one year to ensure stability. 
 
3.2.1.2 cDNA Synthesis 
 
For qRT-PCR, 0.1 μg of total RNA was reverse transcribed into cDNA with 
SuperScript II (Invitrogen) according the manufacturer’s instruction.  The resulting 
template cDNA was purified through Micro Bio-Spin P-30 Chromatography Columns 
(BioRad) to reduce background fluorescence.  
 
3.2.1.3 RNA Primers 
  
Quantitative RT-PCR primers were designed with Primer3 software [111] with 
the following criteria: 
• primer size should be between 20 and 22 (optimally 22) 
• Tm should be matching and within 55°C to 65°C (optimally 65°C because this 
matches the melting temperature for the c-Myc primer set) 
• product Tm optimally 80°C 
• the percentage of G to C binding should be between 50–60% (optimally 55%) 
• the last 5 bases at the 3 prime end should have no more than two G's or C's 
• annealing temperatures of the primers as close as possible 
• primer pairs with minimal number of potential primer dimers and primer hairpins 
as possible 
 
From these criteria, four possible binding pairs were selected for each gene 
(Sigma Genosys).  Primer efficiency was determined for each primer set at 8 
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temperatures ranging from 55–65°C.  The optimal primer set for each gene was used at 




Table 1: Primer Sets for qRT-PCR on MyiQ Cycler 
Gene Primer Sequence Tm (°C) 
c-MYC 5'- GCTGCTTAGACGCTGGATTP -3' 
5'- TCCTCCTCGTCGCAGTAGA -3' 
65 
ACTIN 5'- CTGGAACGGTGAAGGTGACA -3' 
5'- AAGGGACTTCCTGTAACAACGCA -3' 
65 
HSP60 5’- AGTCAAGGCTCCAGGGTTTGG -3' 
5'- TGGCATCGTCTTTGGTCACA -3' 
65 
PCNA 5'- CCTGACAAATGCTTGCTGACC -3' 
5'- CTTGAGGATGGAGCCCTGGA-3' 
63.1 
VEGF 5'- TTTGCTTGCCATTCCCCACT -3' 





Genes were analyzed on a MyiQ Cycler (Bio-Rad).  Quantitative RT-PCR was 
performed according to the following protocol: each 16µl reaction contained 1x iQ Sybr 
Green Supermix (Bio-Rad), 0.3 µM of forward and reverse primers, and 1:2 dilution of 
cDNA.  Reactions were carried out in a MyiQ Single-Color Real-Time PCR Detection 
System (Bio-Rad).  Amplification conditions were as follows: Tm (50 sec), 95°C (60 sec); 
40 repetitions.  The appropriate number of cycles was determined in preliminary 
experiments to ensure that PCR was taking place in the linear range, in order to guarantee 
a proportional relationship between input RNA and densitometry readout.  Absolute 
concentrations were quantified from CT values with a linear standard curve and 
normalized to β-actin expression.  Each PCR was repeated at least 4 times. 
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3.2.2 Western Blotting 
 
HUVEC exposed to cyclical stretch (0–20% elongation) were harvested by 
scraping and then centrifuged (1500 rpm) for 10 min at 4°C.  The pellet was resuspended 
and homogenized by syringe needle in 100–150 µl Cell Lysis Buffer (CLB) [50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 2 mM EDTA], and the supernatants 
were collected and stored frozen at -80°C.  Protein content was determined by Bradford 
assay (Bio-Rad) using CLB as the standard.  Equal protein was resolved by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% Tris-HCl 
precast polyacrylamide gels (Bio-Rad).  Proteins were electroblotted onto nitrocellulose.  
Blots were incubated for 1 hour at room temperature with 3% non-fat dried milk to block 
non-specific binding.  Proteins were revealed with primary antibodies [rabbit anti-
(c-Myc) monoclonal (Cell Signaling); mouse anti-(VEGF) polyclonal (Santa Cruz 
Biotechnology); goat anti-(HSP60) polyclonal (Assay Designs); rabbit anti-(PCNA) 
polyclonal (Santa Cruz Biotechnology)] (1:1000) overnight at 4°C.  Next, blots were 
incubated with secondary antibodies [horseradish peroxidase-conjugated polyclonal anti-
(rabbit IgG), anti-(mouse IgG), or anti-(goat IgG)] (1:10000) for 1 hour at room 
temperature.  Protein was detected with an enhanced chemiluminescence detection 
system (Amersham Biosciences).  Equal protein loading was verified by mouse-anti-
(ß-actin) monoclonal antibody (Sigma-Aldrich).  Western blots were quantified using 
densitometry (Kodak EDAS 1D Imaging System). 
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3.2.3 Quantitative Protein ELISA 
 
TransAM (Active Motif) is a sensitive, quantitative enzyme-linked 
immunosorbent assay (ELISA) for transcription factor activation. This kit uses a plate to 
which the consensus-binding site oligonucleotide for c-Myc has been immobilized.  
Nuclear extract from cyclic strain samples is added to each well and c-Myc binds 
specifically to this bound oligonucleotide. A primary antibody specific for an epitope on 
the bound and active form of c-Myc is then added, followed by secondary antibody and 
developing solution.  Absorbance was measured using a Wallac Victor microplate reader 
(Perkin-Elmer) at 450 nm. 
 
3.2.4 Cell Viability Assays 
 
 
3.2.4.1 CellTiter Cell Proliferation Assay 
 
In vitro cytotoxicity assays were performed using the CellTiter 96 nonradioactive 
cell proliferation assay (Promega). Cells were plated in 0.1 mL of media on day 0 in 
96-well microtiter plates. On day 1, 10 μL of serial dilutions of the investigational 
compound were added in replicates of four to the plates.  After incubation for 4 days at 
37°C in a humidified incubator, 20 μL of a 20:1 mixture of 2 mg/mL MTS [3-(4,5-
dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt] and an electron coupling reagent, phenazine methosulfate (0.92 mg/mL in DPBS), 
were added to each well followed by incubation for 4 hours at 37°C.  Absorbance was 
measured using a Wallac Victor microplate reader (Perkin-Elmer) at 490 nm.  Data were 
expressed as the percentage of survival of the control calculated from the absorbance 
corrected for background absorbance.  The surviving fraction of cells was determined by 
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dividing the mean absorbance values of the test agents by the mean absorbance values of 
the untreated control.  
 
3.2.4.2 BrdU Cell Proliferation Assay 
 
Chemicon's BrdU Cell Proliferation Assay Kit was used to evaluate cell cycle 
progression of HUVEC subjected to quiescent media.  This kit uses bromodeoxyuridine 
(BrdU) to immunochemically detect the population of cells which are synthesizing DNA.  
BrdU is incorporated into newly synthesized DNA strands of actively proliferating cells 
and absorbance was measured using a Wallac Victor microplate reader (Perkin-Elmer) at 
wavelength 450nm.  Data are expressed as the BrdU absorbance corrected for 
background absorbance.  
 
3.2.4.3 Cell Cytotoxicity Assay 
 
CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega) is a 
cytotoxicity assay used specifically to measure necrosis in a system.  Since lactate 
dehydrogenase (LDH) is produced in HUVEC with damaged membranes, by quantifying 
the amount of LDH released into cell culture media, the number of lysed cells can be 
determined.  The enzymatic assay functions by measuring the fluorescence created in the 
reaction of LDH with resazurin.  Immediately after stretch and, if applicable, drug 
exposure, cyclic strain chambers were relocated to a laminar hood and a 100 μL sample 
of cell culture media was removed for analysis.  The kit was used according to the 
manufacturer’s protocol. Absorbance was measured using a Wallac Victor multilabel 
counter (Perkin-Elmer) at 490 nm. Data were expressed as relative necrosis, which is the 
absorbance of the stretched fraction divided by the absorbance of the static fraction. 
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3.2.4.4 Cell Apoptosis Assay 
 
Apo-ONE Homogeneous Caspase-3/7 Assay (Promega) is used to detect 
apoptosis in a system.  This kit fluorescently detects the presence of caspase-3 and -7 
(apoptosis markers) in cells by utilizing Promega's proprietary lysis/activity buffer, in 
conjunction with the (Z-DEVD)2-Rhodamine 110 substrate. Absorbance was measured 
using a Wallac Victor multilabel counter (Perkin-Elmer) at 490 nm.  Data were expressed 
as relative apoptosis, which is the absorbance of the stretched fraction divided by the 
absorbance of the static fraction. 
 
3.2.5 Preparation of Drug Compound 
 
Compounds were synthesized at University of Arizona Cancer Center and 
authenticated through nuclear magnetic resonance and liquid chromatography-mass 
spectrometry.  Lyophilized drug compound was shipped overnight from the University of 
Arizona Cancer Center to Georgia Tech.  Upon arrival, the compound was resuspended 
in 100% 0.02 μm filtered-sterilized DMSO at 10mM and frozen at -20°C until use.  
Repeated freeze/thaws of the compound were avoided.  Upon use, the compound was 
thawed at room temperature and diluted to 100 μM in 0.02 μm filtered deionized water.   
The compound was then diluted to its final concentration of 5 μM in the quiescent media.  
Specifically, the quiescent media was removed, drug added, and then added back to the 
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3.3 Data Analysis 
 
Significance in protein expression was assessed by Student’s t-test.  Data are 
expressed as mean ± SE. Student's t-test was used for the comparisons between the 
different groups. Differences were considered significant (P<0.01 or P<0.05) as indicated 
















   
44 




4.1 Morphological Analysis 
 
To test the accuracy of the cyclic strain system, it was imperative to examine 
whether stretching the silicone substrate resulted in cell stretch and to determine if 
HUVEC responded appropriately to the application of this cyclic strain.  Previously 
published studies [105] using a precursor of the stretching apparatus employed for this 
dissertation examined the mechanical effects of cyclic strain on the morphology of 
HUVEC.  The results found that EC most frequently aligned 90° away from the direction 
of stretch.  Additionally, in visualizing the cytoplasmic microtubule complexes, there was 
a greater density of microtubules running parallel to the major axis of the cell after 
stretch–induced alignment.  Upon replication of these previous morphological analyses, it 
was determined that in fact, the cells do align perpendicular to the direction of stretch, not 
only at pathological levels of cyclic strain, but also at percentages as low as 5%.  This 
altered morphology occurs as soon as 15 minutes after the initiation of stretch. 
Comparable to previous studies on cyclic strain, cells in less confluent sections of 
the membrane aligned more rapidly.  Static membranes failed to align at a specific angle 
and had an essentially random pattern.  Figure 4.1 shows the morphology of stretched and 
static HUVEC. 
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In order to discount the possibility of apoptotic and necrotic induction by the 
experimental system, it was necessary to assay cell necrosis and apoptosis 
simultaneously.  The CytoTox-ONE Homogeneous Membrane Integrity Assay 
(Promega) and the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega) were 
multiplexed.  Although necrosis and apoptosis both ultimately conclude with cell death, 
necrosis is traumatic cell death resulting from acute cellular injury, while apoptosis is 
carried out in an orderly process [112]. 
The CytoTox-ONE Homogeneous Membrane Integrity Assay measures the 
release of lactate dehydrogenase (LDH) into the cell culture media.  LDH levels were 
measured when the cells were cyclically strained at the maximum percentage, 20%, 
because higher strains implicate a higher probability for cell injury.  As shown in Figure 
4.2, there was no increase in release of LDH by 20% stretch for the 0–3 hour time range.  
Thus, 20% cyclic strain of HUVEC had comparable results to static conditions, 
implicating that cyclic straining of cells causes cell deformation without significant cell 
injury.   
Static 
1 Hz, 20% 
Stretched 
Cyclic Strain 
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Next, the effect of cyclic strain on EC apoptosis was detected using the Apo-ONE 
Homogeneous Caspase-3/7 Assay, which employs a luminescent substrate to detect 
caspase-3/7 activity.  The caspases, a family of cysteine proteases, mediate apoptosis at 
different stages.  With activation, they disable cellular housekeeping and repair programs 
and cleave important structural components in the cells [112]. 
Numerous studies on VSMC and EC using various techniques for apoptosis 
detection have shown that physiological levels of cyclic strain (5% to 10%) do not induce 
apoptosis [3, 113, 114].  However, higher potentially pathological levels of strain (15% to 
20%) stimulate apoptosis on both vascular cell types [3, 12, 114-116].  Cyclic strain has 
been shown to activate p53 and Bcl-2 and cause the production of reactive oxygen 
species [116].  These events result in direct oxidative DNA damage.  Therefore, a slight 
increase in apoptosis was expected with 20% cyclic strain.  Figure 4.3 demonstrates that 
20% cyclic strain causes a slight increase in caspase activity.  
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4.2 Quiescent HUVEC 
 
It is well-known that serum exerts strong and rapid control over c-Myc expression 
in numerous cell types [117].  Therefore, in order to monitor basal levels of c-Myc, cells 
are often serum-starved in “quiescent media,” inducing a quiescent growth state.  
Quiescent media is identical to normal media, except it has a low serum content (5% 
versus 20%) and does not contain endothelial growth factor or heparin.  It has been 
established that c-Myc is not expressed in quiescent cells [118], but the length of time 
necessary for specific cell types to become quiescent is imprecisely known.  For that 
reason, before any c-Myc analysis could be undertaken, it was imperative to determine a 
sufficient time period for pre-incubation of HUVEC with quiescent media.   
Bromodeoxyuridine (BrdU) is commonly used to determine if cells are 
proliferating, and thus, is an indicator of whether cells are in a quiescent (G0) state.  
During the S-phase of the cell cycle, BrdU is incorporated into the newly synthesized 
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DNA of replicating cells, substituting for thymidine.  Although this method gives an 
indication of cell quiescence, unfortunately, it has limitations.  Cells in serum-starved 
experiments have previously been determined to not only be quiescent, but also maintain 
positive BrdU staining [119].  This apparent contradiction is explained by the process of 
apoptosis.  Serum and growth factor deprivation induce cells, such as HUVEC, to 
undergo apoptosis.  Researchers report that during this programmed cell death, cells 
depart from their quiescent state and experience some part of the G1 phase of the cell 
cycle, thus explaining their positive BrdU staining.  It is hypothesized that the reason may 
be due in part to the process of apoptosis requiring the presence of newly synthesized 
proteins [119]. 
Thus, bearing these limitations in mind, Chemicon’s BrdU Cell Proliferation 
Assay Kit was employed as an efficacious means to evaluate alterations in cell cycle 
progression of HUVEC subjected to quiescent media.  HUVEC change morphology and 
die when deprived of serum and growth factors for more than 16 hours (based upon 
morphological analysis).  For this reason, and taking into account that HUVEC will 
spend up to 4 hours in quiescent media during cyclic strain experiments, 12 hours was 
determined to be the maximum incubation period.  Therefore, cells were incubated up to 
12 hours in quiescent media and assayed at 2–hour intervals.  Results are shown in Figure 
4.4. 
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Figure 4.4: BrdU staining of HUVEC cultured in quiescent media for 0–12 hours, 
n=4. 




Based upon these results, it was determined that a 12–hour incubation with 
quiescent media was necessary in order to attain a significant change in BrdU 
incorporation.  Although there was not a major decrease in positive BrdU staining, the 
deficit was sufficient to assume cell quiescence without incurring apoptosis.  
Consequently, EC were incubated in quiescent media for 12 hours prior to stretch 
experiments.  Subsequently, all cyclic strain experiments were performed in the same 
quiescent media, ensuring no addition of serum or growth factors, which could alter 
c-Myc expression. 
 
4.3 c-Myc Expression in EC subjected to cyclic strain 
 
To examine the impact of cyclic strain on c-Myc expression, an in vitro system 
mimicking the hemodynamic conditions associated with cyclic strain was employed.  
With any in vitro cyclic strain model, cells are concomitantly exposed to low fluid 
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motion–induced shear stress and convective transport.  Since fluid agitation may alter 
gene expression, the utilized cyclic strain system accurately takes into account the fluid 
agitation inherent in the strain apparatus.  This is accomplished by including a motion 
control (MC) condition.  The devices used in many strain studies do not allow for a 
motion control; therefore, many of the reported cellular responses to cyclic strain (CS) 
have not been confirmed as actual stretch responses (for a detailed description of the 
strain unit, please see Section 3.1.1.3).  
It has been well documented that normal physiological cyclic strain can be 
modeled as about 10% [6, 13], and pathological strain as about 20% [3, 12].  Since it has 
also been established that higher c-Myc levels correspond with pathological states [50, 
61, 66], a direct correlation can be made between c-Myc expression and cyclic strain 
percentage.  Preliminary studies using the imposed cyclic strain model examined if 
fluctuations in cyclic strain percentage were associated with changes in c-Myc 
expression.  HUVEC were subjected to 10% or 20% cyclic strain for 1.75 hours.  Results 
are shown in Figure 4.5.  
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Figure 4.5: Physiological and pathological c-Myc mRNA expression in HUVEC 
HUVEC were subjected to physiological and pathological levels of cyclic strain for 1.75 
hours, n=4–9. 
** Significance (P<0.01) vs. static control 




In comparing 20% CS to static and 10% CS samples, it is apparent that c-Myc 
mRNA expression at 20% CS is almost 3 times that of the other conditions.  Since 
expression of c-Myc in the normal cell is tightly regulated, this expression change has 
enormous implications for downstream targets.  In fact, the normal cell expresses little 
c-Myc unless prompted by external signals, such as growth factors and extracellular 
matrix contacts.  Even then, changes are on the order of only a 1- to 1.5-fold increase. 
Additionally, 20% CS is significant over the motion control, meaning that the 
increased c-Myc expression is due to the actual stretching of the cells and not just to the 
motion of fluid across them.  Based upon these results, it can be summarized that 20% 
cyclic strain does indeed infer a more “pathological” state of cyclic strain. 
To further investigate the correlation between in vitro cyclic strain and in vivo 
conditions, the cyclic strain regimen from 0–20% was examined.  Figure 4.6 shows 
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c-Myc mRNA expression in HUVEC subjected to 1.75 hours of cyclic strain at 5%, 10%, 








































Figure 4.6: c-Myc mRNA expression in HUVEC cyclically strained 0–20%. 
HUVEC were subjected to cyclic strain at percentages of 0-20% for 1.75 hours, n=4–9. 
** Significance (P<0.01) vs. static control 
* Significance (P<0.05) vs. static control 




 From the results in Figure 4.6, we can again see that c-Myc expression is 
significant in the 15–20% range—the range previously implicated as modeling a 
pathological state in the vasculature.  Thus, having established and confirmed the in vitro 
conditions necessary to model in vivo conditions, experiments could now be confidently 
and competently preformed to examine the time-dependency of c-Myc expression.  
c-Myc mRNA expression, as measured by qRT-PCR, was examined at the 
following time-points: 0, 0.5, 1, 2, 3, 4, 5, 6, and 12 hours.  As shown in Figure 4.7, 
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expression increased almost 3-fold in HUVEC cyclically-strained at 20% for 1.5 to 2 










































Figure 4.7: c-Myc is induced by cyclic strain and is time-dependent 
HUVEC were subjected to 20% cyclic strain for 0–12 hours and c-Myc mRNA 
expression was examined in comparison to motion control and static samples, n=4–13. 
** Significance (P<0.01) vs. static control 
++ Significance (P<0.01) vs. motion control 




This upregulation is time-dependent, returning to basal levels by 3 hours.  Also, 
the motion controls did report a very slight, but not significant, increase in expression.  
This finding implicates that the slight movement of media is not a factor in determining 
the cyclic strain–induced gene expression profile.  Therefore, for the purposes of 
simplification, the motion control data will only be reported in Appendix A. 
Western analysis also indicates that 20% cyclic strain induces a time-dependent 
increase in c-Myc protein expression, which peaks around 2 hours (Figure 4.8).   
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Figure 4.8: Western blot analysis of c-Myc protein 
A. Band intensities from densitometry of 6 independent experiments were normalized to 
ß-actin. 
* Significance (P<0.05) vs. static control    
































































Figure 4.9: c-Myc protein expression as measured by TransAM ELISA, n=2–3. 
** Significance (P<0.01) vs. static control 
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Through the use of transcriptional profiling, these results demonstrate significant 
changes in endothelial cell c-Myc gene expression with imposition of pathological levels 
of cyclic strain.  Specifically, both mRNA and protein expression of c-Myc is induced in 
a time-dependent manner by 20% cyclic strain. 
 
4.4 Compound screening to modulate c-Myc transcription 
 
Having established that c-Myc expression is induced by pathological levels of 
cyclic strain, the question arises whether it is possible to modulate this activation.  As 
detailed in Section 2.5.1.2, University of Arizona Cancer Center (UAZCC) in Tucson has 
identified compounds targeted to the c-Myc promoter, which are able to prevent c-Myc 
transcription in cancer cells.  In order to study whether cyclic strain–induced c-Myc 
transcription can also be attenuated, three lead UAZCC compounds were investigated—
compounds 0005, 0010, and 0012. 
The toxicity of each drug was determined by using a cell proliferation assay 
(CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega).  The LD50, 
the concentration of drug at which 50% of cells die, was calculated to be the following 




Table 2: LD50 of UAZCC Compounds 
 
 COMPOUND 0005 COMPOUND 0010 COMPOUND 0012 




These results indicate a high level of toxicity for Compound 0010.  Compounds 
0005 and 0012 are more viable options for HUVEC treatment.  
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In discussing toxicity, it should also be noted that the lyophilized compounds 
have been dissolved in dimethyl sulfoxide (DMSO).  DMSO is often chosen as an ideal 
solvent due to its ease in dissolving solutes.  However, with in vivo use, this same 
property raises safety issues.  These concerns are easily avoided in this experimental 
setup, however, because the compounds are in cell culture for a very short incubation 
time and the final concentration of DMSO is extremely low (0.05%).  In fact, the FDA 
has approved the clinical use of DMSO at 100-fold higher concentrations.  Patients 
inflicted with interstitial cystitis and intractable cerebral edema are routinely treated with 
50% and 10% DMSO, respectively [120]. 
As further confirmation that DMSO is not hindering the cells or inducing 
secondary responses, HUVEC were treated with 0.05% DMSO.   The minimal addition 
of DMSO did not induce any noticeable cell differentiation, such as death, change in 
morphology, or alteration in cell doubling time.  DMSO-treated samples yielded 
responses comparable to untreated samples (Figure 4.10). 
 
 
































Next, to evaluate the efficacy of each of these compounds in the cyclic strain 
experimental setup, a preliminary time course experiment was performed.  Since cyclic 
strain’s effect on c-Myc levels parallels that of treating cells with serum, results were 
expected to mirror those of University of Arizona’s serum-starvation experiment in 
cancer cells (see Section 2.5.1.2).  For this preliminary experiment, all drugs were used at 
1 µM for at least 24 hours.  Cells were seeded in normal HUVEC media.  For 12 hours, 
HUVEC were placed in normal media containing 1 µM of drug, washed, and then treated 
for an additional 12 hours in quiescent media containing drug.  cDNA from 20% cyclic 
strain and motion control samples was then collected from the following time-points: 0, 
0.5, 1, 1.5, 2, 2.5, and 3 hours.  The results from each drug were as follows (Figures 4.11, 
4.12, and 4.13). 
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Figure 4.13: Compound 0012, n=1. 
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From these preliminary evaluations, it was concluded that compound 0012 is non-
toxic and the most effective at attenuating c-Myc levels, while 0010 and 0005 are 
essentially inconsequential.  From a drug development point of view, the failure of a 
compound is due to a number of limitations, which are disease and cell-type specific.  A 
compound with suboptimal chemical properties may be toxic or unable to penetrate the 
cell nucleus due to its stereochemistry and/or hydrophobicity.  The efficacy of compound 
0012 reveals that it is indeed possible to attenuate c-Myc expression by targeting the 
silencer region of the c-Myc promoter. 
 
4.5 Compound Optimization 
 
As the target compound for further analysis, the usage of compound 0012 was 
further optimized to maximize its ability to attenuate c-Myc expression.  
 
4.5.1 Compound 0012 Dosage 
 
In order to determine the optimal concentration of 0012 to use, cells were 
subjected to 1.75 hours of cyclic strain and treated with the following concentrations of 
0012: 0µM, 0.5µM, 1µM, 2.5µM, 5µM, 10µM, 15µM, 25µM, and 50µM.  Results are 
graphed in Figure 4.14. 
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Figure 4.14: Compound 0012 dose response 
c-Myc mRNA expression was examined in HUVEC that were cyclically strained for 1.75 
hours and treated with varying concentrations of Compound 0012, n=1–5. 




By comparing the treated cyclic strain samples to 0 µM, it is apparent that 
compound 0012 is most effective at concentrations of 5 µM and 10 µM.  Since 5 µM is a 
slightly lower concentration of DMSO (0.05% as compared to 0.1%), it was chosen as 
the optimal treatment concentration. 
 
4.5.2 Compound 0012 Time Treatment 
 
The next step in optimizing compound 0012 efficacy was to determine the 
optimal dosing schedule.  A treatment time course was investigated as follows (Table 3).  
Shading is indicative of 5 µM of compound 0012 in the media.  For all samples, at 12 
hours prior to stretch, normal media was removed and replaced with quiescent media.  
For example, “36 hours” refers to cells that were given drug in regular media 36 hours 
prior to stretch, then replaced with quiescent media without drug.  Since normal cells are 
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in a G0 state and only express the gene when they actively divide, the “0 hrs” time point 









 The results of the time treatment experiment are shown in Figure 4.15. 
 
 



































Figure 4.15: Time treatment experiment, n=2–5. 
## Significance (p=0.01) vs. untreated HUVEC 
# Significance (P<0.05) vs. untreated HUVEC 
 
 




Condition 1: “O hrs” 
Condition 2: “12 hrs” 
Condition 3: “24 hrs” 
Condition 4: “24* hrs” 
Condition 5: “36 hrs” 
Condition 6: “NO Drug” 
Normal 
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Interestingly, the optimal results were seen in the “0 hrs” treatment in which the 
drug was added as stretch began.    The “0 hrs” treatment resulted in an attenuation of 
c-Myc expression by 40%.  Comparing this data to UAZCC’s serum-starvation 
experiment with cancer cells, “0 hrs” treatment parallels adding serum back in the cancer 
cell experiment. 
The other time points also yielded interesting results.  At “12hrs”, there was no 
effect.  This result could indicate that HUVEC must be in a nondividing G0 state in order 
for the drug to be effective.  The results for the “24 hrs”, “24* hrs”, and “36 hrs” indicate 
that perhaps the drug is being metabolized.  This could explain why “24 hrs” and “24* 
hrs” attenuated cyclic strain effects by 15% and 25%, respectively, and “36 hrs” had no 
effect at all. 
 
4.6 Modulation of c-Myc Transcriptional Activation 
 
After determining the best possible conditions for using compound 0012, its 
success in modulating cyclic strain induced c-Myc expression was evaluated.  HUVEC 
were seeded onto silicone membranes in normal media.  Twelve hours prior to the 
initiation of cyclic strain, quiescent media replaced the normal media.  At the time of 
stretch, the quiescent media was removed and mixed with compound 0012 to give a final 
concentration of 5 μM.  The compound-containing quiescent media was then returned to 
the stretching apparatus and cyclic strain experiments commenced.  c-Myc mRNA 
expression with and without compound 0012 was examined at the following time-points: 
0, 0.5, 1, 2, 3, 4, 5, 6, and 12 hours.  As shown in figure 4.16, at peak c-Myc expression, 
compound 0012 succeeds in attenuating mRNA transcriptional activation about 33% and 
28% at 1 and 2 hours, respectively. 












































Figure 4.16: Compound 0012 attenuates c-Myc mRNA expression, n=4–13. 
** Significance (P<0.01) vs. static conditions 




Western analysis also indicates that cyclic strain–induced c-Myc expression can 
be modulated at the protein level.  As shown in Figures 4.17, c-Myc protein expression is 
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Figure 4.17: Compound 0012 attenuates c-Myc protein expression 
A. Compound 0012 attenuates c-Myc protein upregulation by cyclic strain.  Band 
intensities from densitometry of 5 independent experiments were normalized to ß-actin. 
# Significance (P<0.05) vs. untreated HUVEC 




4.7 Necrosis and Apoptosis  
 
Although results indicate that c-Myc transcription can be attenuated through the 
use of compound 0012, it is imperative to ensure that this outcome is due to c-Myc 
promoter targeting, and not as a secondary result of necrosis and/or apoptosis.  As 
detailed in Section 4.1, the CytoTox-ONE Homogenous Membrane Integrity Assay and 
the Apo-ONE Homogenous Caspase-3/7 Assay were used to determine levels of necrosis 
and apoptosis.  These two assays were performed as described before—HUVEC were 
cyclically strained at 20%, but now, 5 μM of compound 0012 was added to the quiescent 
media at the time of stretch.  Results for necrosis and apoptosis are shown in Figures 4.18 
and 4.19, respectively.    
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From these figures, it is apparent that the addition of compound 0012 does not 
induce HUVEC necrosis or apoptosis.  Therefore, it is unlikely that the attenuation of 
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4.8 c-Myc Downstream Target Genes 
 
The subsequent step in studying the modulation of c-Myc focuses investigations 
on the genetic profile downstream targets of c-Myc.  These are genes whose expression is 
directly regulated by the c-Myc protein.  It is well known that c-Myc induction leads to 
activation of numerous genes with a wide range of functions, including regulating cell 
proliferation, apoptosis, differentiation, morphology, migration, and secretory function.  
Of interest to this dissertation are genes related to cardiovascular disease.  Three genes in 
particular have been identified as both regulated by c-Myc and as playing a significant 
role in the progression of vasculoproliferative cardiovascular diseases.  These c-Myc 
downstream target genes are proliferating cell nuclear antigen, heat shock protein 60, and 




Proliferating cell nuclear antigen (PCNA) mRNA expression of HUVEC 
subjected to cyclic strain is shown in Figure 4.20.  As expected from the review of 
relevant literature, this graph shows that cyclic strain does indeed induce PCNA 
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Figure 4.20: PCNA mRNA expression, n=3–10. 
* Significance (P<0.05) vs. static control 
# Significance (P<0.05) vs. untreated HUVEC 




Western analysis (Figure 4.21) also indicates that 20% cyclic strain induces 
PCNA protein expression, which can also be attenuated by treatment with compound 





Figure 4.21: PCNA protein expression 
A. Compound 0012 attenuates PCNA protein upregulation by cyclic strain.  Band 
intensities from densitometry of 5 independent experiments were normalized to ß-actin. 
* Significance (P<0.05) vs. static control 
# Significance (P<0.05) vs. untreated HUVEC 
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Vascular endothelial growth factor (VEGF) mRNA expression of HUVEC 
subjected to cyclic strain is shown in Figure 4.22.  As expected from the review of 
relevant literature, this graph shows that cyclic strain does indeed induce VEGF 













































Figure 4.22: VEGF mRNA expression, n=3–12. 
** Significance (P<0.01) vs. static control 
* Significance (P<0.05) vs. static control 
## Significance (P<0.01) vs. untreated HUVEC 




Western analysis also indicates that 20% cyclic strain induces VEGF protein 
expression, which can also be attenuated by treatment with compound 0012 (Figure 
4.23). 
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Figure 4.23: VEGF protein expression 
A. Compound 0012 attenuates VEGF protein upregulation by cyclic strain.  Band 
intensities from densitometry of 5 independent experiments were normalized to ß-actin. 
* Significance (P<0.05) vs static control 
# Significance (P<0.05) vs. untreated HUVEC 




These results are consistent with other researchers who have found VEGF 




Heat shock protein 60 (HSP60) mRNA expression of HUVEC subjected to cyclic 
strain is shown in Figure 4.24.  As expected from the review of relevant literature, this 
graph shows that cyclic strain does indeed induce HSP60 expression and that the addition 
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Figure 4.24: HSP60 mRNA expression, n=3–9. 




Although the effect of compound 0012 is not significant for mRNA expression, 
there is a slight decrease in expression.  For all of these downstream genes, the genetic 
profile is essential at the mRNA level, but more important at the protein level, where 
cellular functions are directly affected.  In the case of HSP60, the effect of the compound 
effect is significant at the protein level (Figure 4.25). 
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Figure 4.25: HSP60 protein expression 
A. Compound 0012 attenuates HSP60 protein upregulation by cyclic strain.  Band 
intensities from densitometry of 4 independent experiments were normalized to ß-actin. 
* Significance (P<0.05) vs. static control 
# Significance (P<0.05) vs. untreated HUVEC 




4.8.4 Overlay of c-Myc Downstream Target Genes 
 
 By plotting the mRNA expression of all three target genes onto one graph, we can 
easily see the time-dependent expression of c-Myc downstream target genes (Figure 
4.26). 
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The mRNA expression of these genes after treatment with compound 0012 is 
compiled in Figure 4.27.  By directly comparing Figures 4.26 and 4.27, it can be inferred 
that compound 0012 succeeds in attenuating the expression of PCNA, VEGF and HSP60.  
Hence, by inhibiting cyclic strain–induced c-Myc transcription, compound 0012 




































Figure 4.27: Compound 0012 attenuates c-Myc downstream gene expression 
Compound 0012 attenuates c-Myc, PCNA, HSP60 and VEGF mRNA expression in 
HUVEC subjected to cyclic strain.
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The primary focus of this research is on the nuclear events that occur in response 
to pathological levels of cyclic strain, specifically, transcription factor c-Myc and its 
downstream gene targets.  However, in studying the effects of mechanical forces on EC, 
it is also important to discuss the mechanisms by which vascular cells sense the 
extracellular mechanical stimuli and convert them into chemical signals.  The aim in 
postulating this mechanotransduction pathway is to aid in the understanding of 
physiological and pathological processes involved in vascular remodeling and 
cardiovascular disease. 
Specific mechanotransductive signaling pathways have not yet been elucidated; 
however, some possible mechanisms can be hypothesized.  Stretch-mediated responses 
can be simplified in five generalized steps.  First, applied mechanical forces are 
transmitted thorough the extracellular matrix to the cytoskeleton.  Second, the 
cytoskeleton responds by activating membrane receptors, including integrins, ion 
channels, platelet-derived growth factor receptors, and G proteins [122].  Third, these 
mechanosensors convert the mechanical stimuli into chemical signals, activating second 
messenger systems.  Next, these molecules transduce the signals from the 
mechanoreceptors to the nucleus.  Finally, the nuclear events result in changes in cellular 
function [123].  It is known that there are different levels of sensing and control at each 
step, but current research is still being undertaken to determine the specific mechanisms.   
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Research shows that transduction of cyclic strain to the nuclear level seems to 
involve the same second messenger pathways and genes as those involved in other 
mechanical forces [124].   These second messengers include mitogen-activated protein 
kinases, protein kinase C, and Akt.  Important to this discussion is second messenger 
adenylate cyclase/cAMP, which has not only been identified as activated by cyclic strain, 
but also has an implicated role in c-Myc expression.  Studies with bovine aortic 
endothelial cells indicate that the activity of adenylate cyclase/cAMP increases within 15 
minutes of 10% cyclic strain.  This induction of adenylate cyclase/cAMP, which does not 
occur at 6% stretch, more than doubles the basal expression levels [115].  These 
experiments provide evidence that when cyclic strain reaches a threshold, the adenylate 
cyclase (AC) signal transduction pathway is activated, stimulating the expression of 
genes containing cAMP-responsive promoter elements. 
Important to this dissertation is the discovery that c-Myc is a gene with this 
promoter element, meaning cAMP is able to activate transcription factor c-Myc [125].  
Therefore, a possible pathway for cyclic strain induced c-Myc is via the activation of 
adenylate cyclase/cAMP.  The diagram shown in Figure 5.1 outlines the possible 
pathway of cyclic strain-mediated EC responses. 
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Figure 5.1: Proposed mechanotransduction pathway for c-Myc 
Pathological levels of stretch induce adenylate cyclase/cAMP which leads to increased 




5.2 c-Myc Control of Gene Expression 
 
Although the mechanical forces initiating vascular disease have been studied 
extensively, their implicated differential gene expression profiles remain relatively 
unknown.  As a starting point for investigation, immediate-early proto-oncogenes, such 
as c-Myc, have been identified as the earliest genetic responses to stimuli.  c-Myc is a 
particularly promising choice because it is shear-inducible [126] and due to its vast 
network of downstream target genes, is referred to as a “global regulator of transcription” 
[127].  In all, c-Myc controls the expression of about 15% (3000-4000 genes) of the 
genome [127].  These target genes are involved in proliferation, apoptosis, metabolism, 
migration, and remodeling. 
   
76 
 Although vast, high-throughput genomic and functional analyses, such as SAGE 
and microarray, have been performed on c-Myc, very few target genes are identified as 
being the most relevant to the progression of vascular diseases.  This lack of data is not 
due to insufficient accomplishment in the field.  Rather, despite numerous studies 
documenting the proliferation markers in human atherosclerotic plaques and restenotic 
lesions, universal acceptance of the “pertinent genes” remains controversial.  Research 
does reveal that the starting events of the stenotic process include cell proliferation, 
migration, apoptosis, deposition of extracellular matrix, and inflammatory reactions [14].   
Accordingly, pertinent c-Myc target genes were chosen based on their roles in 
these initiation events.  Together, the selected genes, VEGF, HSP60 and PCNA, are three 
markers often simultaneously monitored for initiation and progression of vascular 
pathologies [128].  Although each gene can be isolated to determine its individual role in 
proliferative cardiovascular diseases, it is their concerted effects which result in the 
culmination of abnormal blood vessel narrowing.  Together, these genes comprise the 
steps implicated in the vasculoproliferative cascade, beginning with regulation of the cell 
cycle and the inflammatory response, and culminating with vascular remodeling. 
Examination of the mRNA and protein expression profile of each gene (Section 
4.8.1–4.8.4) presents the opportunity to hypothesize a potential timeline governing this 
proliferative process.  It is reasonable to postulate that upregulation of c-Myc quickly 
triggers the expression of PCNA and HSP60, while VEGF is induced slightly later and 
sustained longer.  These time points can be further substantiated by extrapolating to the 
known progression of events in vivo.  Animal studies suggest that vascular cell 
proliferation is the prevailing event in the initiation of vascular diseases [51].  Not only 
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are all three genes intimately linked to regulating the cell cycle, each gene mediates its 
effects at a different phase.  Thus, their concerted expression allows direct cell cycle 
regulation at the G1, S, and G2 phases.  VEGF can directly stimulate cell cycle 
progression from the G1 to S phase [129] and can mediate indirect effects through cell 
cycle regulators [130].  PCNA is essential for the S phase of the cell cycle.  Lastly, heat 
shock proteins protect cells from apoptosis and reverse cell-arrest in the G2 phase [131]. 
After early cell proliferation, likely mediated by the expression of HSP60 and 
PCNA, arterial remodeling begins at the site of intimal injury.  This later process, alike to 
the reported expression of VEGF, is sustained.  In addition, the implicated roles of VEGF 
implicated roles, such as wound healing, neovascularization, and EC migration [37], are 
pivotal to vascular remodeling.  Hence, these parallels corroborate the argument that 
remodeling is at least partly accomplished through the activation of VEGF. 
In conclusion, the upregulation of c-Myc by cyclic strain leads to the expression 
of c-Myc downstream targets.  These genes can be implicated in comprising the steps of 
the vasculoproliferative cascade, beginning with regulation of the cell cycle and the 
inflammatory response, and culminating with vascular remodeling. 
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5.3 Drug-Eluting Stents 
 
A promising contribution of this research is the identification of a possible novel 
treatment for vascular disease.  Restenosis after surgical intervention is a major clinical 
problem, occurring in 30-50% of patients [16, 17].  Anti-coagulants, anti-inflammatories, 
and anti-proliferative drugs have been unsuccessful at preventing restenosis [132].  
Ideally, the most effective pharmacological solution to preventing restenosis is the 
controlled-release of an anti-proliferative drug directly targeted to the factors involved in 
vascular injury. 
Based upon these ideal drug characteristics and the data reported in this 
dissertation, compound 0012 is an excellent candidate for the treatment of in-stent 
restenosis.  Results demonstrate not only the effectiveness of compound 0012 in reducing 
c-Myc protein expression (by more than 50%), but also in attenuating (to different 
extents) the expression of downstream genes (VEGF, HSP60, and PCNA) that contribute 
to vascular remodeling pathologies.  It can be postulated based upon the roles of these 
genes that compound 0012 inhibits key targets in the cell cycle, while also potentially 
preventing inflammation and vascular remodeling.   
 Additionally, the chemistry of compound 0012 makes it an ideal anti-restenotic 
drug because it contains hydrophobic elements, which ensure high local concentrations, 
and hydrophilic elements, which allow homogeneous drug diffusion.  Most importantly, 
since compound 0012 has been identified as specifically targeting the factors involved in 
vascular injury, its use can be short-lived and thus, will not inhibit re-endothelialization 
of the intima.  Therefore, the fear that drug-eluting stents (DES) cause late stent 
thrombosis is abrogated.  
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Despite these encouraging in vitro results with compound 0012, several questions 
remain to be answered.  Recalling that c-Myc controls up to 15% of the genome, the use 
of compound 0012 must be tethered by the concern for attenuating essential downstream 
genes.  Additionally, compound 0012 must be proven to be anti-thrombotic, anti-
inflammatory, anti-proliferative, and non-toxic in vivo.  Once confirmed to be safe and 
efficacious, it needs to be determined if compound 0012 readily diffuses across vascular 
tissue and achieves high local tissue concentration.  The standard pharmacology for in 
vivo animal models and, later, human clinical trials will also need to be determined.  
Specific to the use of compound 0012 in DES, research will have to be completed to 
identify a biocompatible polymer able to deliver the drug at a sustained, controlled, and 
predictable rate.  However, the successful completion of these studies could culminate in 
the development of a novel therapeutic opportunity to treat vasculoproliferative diseases. 
 
5.4 Limitations of Experimental Setup 
 
The extrapolation of these results to in vivo conditions must be tempered by the 
understanding that all in vitro experimental models have limitations.  Specific to this 
setup are cell culture and hemodynamic restrictions. 
An idealized in vivo experiment is limited at even the cellular level.  The use of 
HUVEC is often criticized as an inaccurate representation of EC behavior because they 
are vein-, not arterial-, derived endothelial cells [109].  Further, once in culture, 
researchers argue whether passaged HUVEC accurately represent in vivo genetic profiles.  
However, since HUVEC are the most economically feasible EC, low passages are 
generally accepted as an accurate representation of arterial EC.  A final concern in cell 
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culture is the fear that by not including VSMC and macrophages, HUVEC are permitted 
to respond differently than they would in vivo. 
From a mechanistic point of view, it is important to point out that, although cyclic 
strain is a major contributor to vascular disease, the arterial blood vessel is also subjected 
to two other forces: hydrostatic compression and shear stress.  An ideal model would 
allow the study of the concerted effects of all three forces.  Additionally, this 
dissertation’s setup incorporated the use of a motion control to account for the small 
movement of media, but these controls are not a perfect reproduction.  Fluid motion is 
possibly slightly greater when the entire substrate is agitated rather than a single edge 
moving.   
The only plausible solution to combat these limitations is the development of a 
novel setup integrating a whole vessel model with all of the hemodynamic forces 
implicated in vascular mechanics.  Since this experimental setup does not yet exist, this 
project employed an optimal uniaxial system to experimentally investigate cyclic strain.  
Very recent data validate this type of bioreactor as the most suited at replicating the 
physiological environment [133].  Therefore, the minimal limitations imposed on this 
experimental setup deem it a reliable method for monitoring the interrelationship between 
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6.1 Summary of Results  
 
Each heartbeat creates a pressure difference between systole (peak pressure, 
corresponding to the opening of the heart valve) and diastole (closing of the valve).  This 
fluctuating difference in pressures causes a pulsatile circumferential expansion of the 
artery called “cyclic strain,” which is normally about 10%.  When certain pathological 
conditions arise in vivo, such as hypertension, atherosclerosis, or after surgical 
intervention, elevated cyclic strain (~20%) can induce vessel remodeling, leading to a 
pro-atherogenic endothelium [3].  Research thus far has been successful in demonstrating 
that different cellular functions are modulated by changes in cyclic strain, but elucidation 
of the mechanisms by which EC alter these functions remains to be detailed. 
This dissertation’s chief goal is to offer a possible mechanism and promising 
clinical treatment for vascular diseases initiated by increased cyclic strain.  The unifying 
theory is that pathological conditions increase cyclic strain in the endothelium, leading to 
plaque formation and intimal thickening, occurring directly due to the induction of 
c-Myc.  In order to substantiate this hypothesis, this study verified that elevated levels of 
cyclic strain (20%) induce c-Myc mRNA and protein expression.  In fact, by justifying 
these pathological levels of cyclic strain, this dissertation presents novel evidence that 
HUVEC c-Myc mRNA and protein expression are induced by 20% cyclic strain in a 
time-dependent manner. 
This study provides evidence that these pathogenic levels of cyclic strain 
specifically activate the c-Myc promoter, leading to c-Myc transcription and downstream 
   
82 
gene induction.  Further, by specifically targeting the c-Myc promoter, it is possible to 
not only modulate c-Myc, but also the downstream gene targets of c-Myc, which are 
prevalent in the induction of vascular disease.  The compounds targeting c-Myc could 
provide a potential therapeutic opportunity in treating vasculoproliferative diseases. 
  
6.2 Recommendations for Future Work  
 
6.2.1 Cyclic Strain Model Enhancements 
 
Based upon experiences with the current cyclic strain apparatus, it is possible to 
offer several possible modifications.  The current methodology poses serious problems 
with HUVEC seeding and adherence, including spillage, patchy seeding, and cell 
detachment.   Furthermore, there are several technical problems, including difficulty in 
sterilizing the multi-component stretch chamber and limitations of the substrate size, 
which often required the pooling of multiple chambers to provide enough cells for 
experimental assay. 
 
6.2.2 Additional Areas for Research 
 
This in vitro work elucidates some of the possible mechanisms of HUVEC gene 
regulation by mechanical stimuli. However, there are several areas for continued 
research.  
• Since this experimental setup only utilized endothelial cells, it would be valuable to 
investigate smooth muscle cell behavior individually and in co-culture with EC. 
 
• An interesting study would be to precondition the cells to “normal” physiological 
conditions (10% CS) and then introduce pathological stretching conditions (20%). 
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• This dissertation focused on three c-Myc downstream gene targets, however, other 
possible genes exist for future investigation.   
o Preliminary research was attempted without success on two c-Myc target 
genes implicated in vascular remodeling: matrix metalloproteinase-9 (MMP-
9) and cyclin dependent kinase 4 (CDK4).  However the limited achievement 
could be due to experimental methodology and further studies are warranted.  
Both genes have been identified as transcriptional targets of c-Myc [90, 134].  
CDK4 is an especially interesting target because it directly correlates to the 
ability of c-Myc to promote vasculoproliferative responses and cell-cycle 
progression.  MMP-9 is only induced by vascular cells during pathogenesis 
and is neither produced under basal conditions nor detectable in healthy 
human arteries. 
 
o Three genes, matrix metalloproteinase-2 (MMP-2), fibroblast growth factor 
(FGF-2), and platelet derived growth factor (PDGF) have been shown to have 
increased expression with cyclic strain and are implicated in the progression 
of vascular obstructive diseases [135-137].  However, current publications 
have not yet identified these genes as downstream c-Myc targets.  The 
establishment of these genes as c-Myc targets could lead to the elucidation of 
more genetic targets in restenosis that can be modulated by attenuating c-Myc 
transcription. 
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Figure A.2: c-Myc mRNA expression in HUVEC cyclically strained 0–20%. 
HUVEC were subjected to cyclic strain at percentages of 0–20% for 1.75 hours, n=4–13. 
** Significance (P<0.01) vs. static control 
* Significance (P<0.05) vs. static control 
++ Significance (P<0.01) vs. motion control 







































Figure A.3: Compound 0012 dose response 
c-Myc mRNA expression was examined in HUVEC that were cyclically strained for 1.75 
hours and treated with varying concentrations of Compound 0012, n=1–5. 
## Significance (P<0.01) vs. untreated HUVEC 


















































Figure A.4 Time treatment experiment, n=2–5. 
## Significance (p=0.01) vs. untreated HUVEC 
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Figure A.5: VEGF mRNA expression, n=3–12. 
** Significance (P<0.01) vs. static conditions 
* Significance (P<0.05) vs. static conditions 
## Significance (P<0.01) vs. untreated HUVEC 
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Figure A.6: HSP60 mRNA expression, n=3–9. 
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Figure A.7: PCNA mRNA expression, n=3–10. 
* Significance (P<0.05) vs. static control 
# Significance (P<0.05) vs. untreated HUVEC 
## Significance (P<0.01) vs. untreated HUVEC 
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Figure B.8: Percent death in HUVEC treated with compound 0012 
  
  






















Figure B.2: Percent death in HUVEC treated with compound 0010 
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Figure B.3: Percent death in HUVEC treated with compound 0005 
 






1. Rosamond, W., et al., Heart disease and stroke statistics--2007 update: a report 
from the American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation, 2007. 115(5): p. e69-171. 
2. Thubrikar, M.J. and F. Robicsek, Pressure-induced arterial wall stress and 
atherosclerosis. Ann Thorac Surg, 1995. 59(6): p. 1594-603. 
3. Liu, X.M., et al., Physiologic cyclic stretch inhibits apoptosis in vascular 
endothelium. FEBS Lett, 2003. 541(1-3): p. 52-6. 
4.   [cited August 14, 2007]; Available from: 
http://www.houstonheartcenter.com/html/heart_healthy.html. 
5. Campbell, N.A., L.G. Mitchell, and J.B. Reece, Biology : concepts & connections. 
1994, Redwood City, Calif.: Benjamin/Cummings Pub. Co. 846. 
6. O'Rourke, M., Mechanical principles in arterial disease. Hypertension, 1995. 
26(1): p. 2-9. 
7. Papadaki, M. and S.G. Eskin, Effects of fluid shear stress on gene regulation of 
vascular cells. Biotechnol Prog, 1997. 13(3): p. 209-21. 
8. Vouyouka, A.G., et al., Ambient pulsatile pressure modulates endothelial cell 
proliferation. J Mol Cell Cardiol, 1998. 30(3): p. 609-15. 
9. Nerem, R.M., Vascular fluid mechanics, the arterial wall, and atherosclerosis. J 
Biomech Eng, 1992. 114(3): p. 274-82. 
10. Wasserman, S.M. and J.N. Topper, Adaptation of the endothelium to fluid flow: in 
vitro analyses of gene expression and in vivo implications. Vasc Med, 2004. 9(1): 
p. 35-45. 
11. Patrick, C.W., Jr. and L.V. McIntire, Shear stress and cyclic strain modulation of 
gene expression in vascular endothelial cells. Blood Purif, 1995. 13(3-4): p. 112-
24. 
12. Haga, J.H., Y.S. Li, and S. Chien, Molecular basis of the effects of mechanical 
stretch on vascular smooth muscle cells. J Biomech, 2007. 40(5): p. 947-60. 
13. Goldsmith, H.L. and V.T. Turitto, Rheological aspects of thrombosis and 
haemostasis: basic principles and applications. ICTH-Report--Subcommittee on 
   
90 
Rheology of the International Committee on Thrombosis and Haemostasis. 
Thromb Haemost, 1986. 55(3): p. 415-35. 
14. Sriram, V. and C. Patterson, Cell cycle in vasculoproliferative diseases: potential 
interventions and routes of delivery. Circulation, 2001. 103(19): p. 2414-9. 
15. Sottiurai, V.S., Comparison of Reversed, Nonreversed Translocated, and In Situ 
Vein Grafts in Arterial Revascularization: Techniques, Cumulative Patency, 
Versatility, and Durability. Int J Angiol, 1999. 8(4): p. 197-202. 
16. Fischman, D.L., et al., A randomized comparison of coronary-stent placement and 
balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis 
Study Investigators. N Engl J Med, 1994. 331(8): p. 496-501. 
17. Serruys, P.W., et al., A comparison of balloon-expandable-stent implantation with 
balloon angioplasty in patients with coronary artery disease. Benestent Study 
Group. N Engl J Med, 1994. 331(8): p. 489-95. 
18. Schwartz, S.M., D. deBlois, and E.R. O'Brien, The intima. Soil for atherosclerosis 
and restenosis. Circ Res, 1995. 77(3): p. 445-65. 
19. Belli, G., S.G. Ellis, and E.J. Topol, Stenting for ischemic heart disease. Prog 
Cardiovasc Dis, 1997. 40(2): p. 159-82. 
20. Hall, G.J. and E.P. Kasper, Comparison of element technologies for modeling 
stent expansion. J Biomech Eng, 2006. 128(5): p. 751-6. 
21. Costa, M.A. and D.I. Simon, Molecular basis of restenosis and drug-eluting 
stents. Circulation, 2005. 111(17): p. 2257-73. 
22. Gorbet, M.B. and M.V. Sefton, Biomaterial-associated thrombosis: roles of 
coagulation factors, complement, platelets and leukocytes. Biomaterials, 2004. 
25(26): p. 5681-703. 
23. Hoffmann, R. and G.S. Mintz, Coronary in-stent restenosis - predictors, 
treatment and prevention. Eur Heart J, 2000. 21(21): p. 1739-49. 
24. Kandzari, D.E., Drug-eluting stent thrombosis: it's never too late. Nat Clin Pract 
Cardiovasc Med, 2006. 3(12): p. 638-9. 
25. Jensen, L.O., et al., Stent thrombosis, myocardial infarction, and death after drug-
eluting and bare-metal stent coronary interventions. J Am Coll Cardiol, 2007. 
50(5): p. 463-70. 
26. Pfisterer, M., et al., Late clinical events after clopidogrel discontinuation may 
limit the benefit of drug-eluting stents: an observational study of drug-eluting 
versus bare-metal stents. J Am Coll Cardiol, 2006. 48(12): p. 2584-91. 
   
91 
27. Lagerqvist, B., et al., Long-term outcomes with drug-eluting stents versus bare-
metal stents in Sweden. N Engl J Med, 2007. 356(10): p. 1009-19. 
28. Nordmann, A.J., M. Briel, and H.C. Bucher, Mortality in randomized controlled 
trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a 
meta-analysis. Eur Heart J, 2006. 27(23): p. 2784-814. 
29. Van Belle, E., et al., Drug-eluting stents: trading restenosis for thrombosis? J 
Thromb Haemost, 2007. 5 Suppl 1: p. 238-45. 
30. Kipshidze, N., et al., Role of the endothelium in modulating neointimal formation: 
vasculoprotective approaches to attenuate restenosis after percutaneous coronary 
interventions. J Am Coll Cardiol, 2004. 44(4): p. 733-9. 
31. Silber, S., Capturing circulating endothelial progenitor cells: a new concept 
tested in the HEALING studies. Minerva Cardioangiol, 2006. 54(1): p. 1-3. 
32. New, G., et al., Estrogen-eluting, phosphorylcholine-coated stent implantation is 
associated with reduced neointimal formation but no delay in vascular repair in a 
porcine coronary model. Catheter Cardiovasc Interv, 2002. 57(2): p. 266-71. 
33. Do, P.N. and C.P. Juergens, Acute stent thrombosis associated with exercise 
testing. Heart Lung Circ, 2004. 13(2): p. 198. 
34. Lewis, A.L., et al., Drug loading and elution from a phosphorylcholine polymer-
coated coronary stent does not affect long-term stability of the coating in vivo. 
Biomed Mater Eng, 2004. 14(4): p. 355-70. 
35. Amols, H.I., Methods to improve dose uniformity for radioactive stents in 
endovascular brachytherapy. Cardiovasc Radiat Med, 1999. 1(3): p. 270-7. 
36. Gruchala, M., et al., Gene therapy for cardiovascular diseases. Curr Pharm Des, 
2004. 10(4): p. 407-23. 
37. Rutanen, J., H. Puhakka, and S. Yla-Herttuala, Post-intervention vessel 
remodeling. Gene Ther, 2002. 9(22): p. 1487-91. 
38. Eslami, M.H., et al., Gene delivery to in situ veins: differential effects of 
adenovirus and adeno-associated viral vectors. J Vasc Surg, 2000. 31(6): p. 
1149-59. 
39. Kutryk, M.J., et al., Local intracoronary administration of antisense 
oligonucleotide against c-myc for the prevention of in-stent restenosis: results of 
the randomized investigation by the Thoraxcenter of antisense DNA using local 
delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol, 
2002. 39(2): p. 281-7. 
   
92 
40. Makinen, K., et al., Increased vascularity detected by digital subtraction 
angiography after VEGF gene transfer to human lower limb artery: a 
randomized, placebo-controlled, double-blinded phase II study. Mol Ther, 2002. 
6(1): p. 127-33. 
41. Tunstall-Pedoe, H., et al., Contribution of trends in survival and coronary-event 
rates to changes in coronary heart disease mortality: 10-year results from 37 
WHO MONICA project populations. Monitoring trends and determinants in 
cardiovascular disease. Lancet, 1999. 353(9164): p. 1547-57. 
42. de Nigris, F., M.L. Balestrieri, and C. Napoli, Targeting c-Myc, Ras and IGF 
cascade to treat cancer and vascular disorders. Cell Cycle, 2006. 5(15): p. 1621-
8. 
43. Spencer, C.A. and M. Groudine, Control of c-myc regulation in normal and 
neoplastic cells. Adv Cancer Res, 1991. 56: p. 1-48. 
44. Marcu, K.B., S.A. Bossone, and A.J. Patel, myc function and regulation. Annu 
Rev Biochem, 1992. 61: p. 809-60. 
45. Blackwood, E.M. and R.N. Eisenman, Max: a helix-loop-helix zipper protein that 
forms a sequence-specific DNA-binding complex with Myc. Science, 1991. 
251(4998): p. 1211-7. 
46. Prendergast, G.C. and E.B. Ziff, Methylation-sensitive sequence-specific DNA 
binding by the c-Myc basic region. Science, 1991. 251(4990): p. 186-9. 
47. Hurlin, P.J., et al., Mad3 and Mad4: novel Max-interacting transcriptional 
repressors that suppress c-myc dependent transformation and are expressed 
during neural and epidermal differentiation. Embo J, 1995. 14(22): p. 5646-59. 
48. Shyy, Y.J., et al., Fluid shear stress induces a biphasic response of human 
monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc 
Natl Acad Sci U S A, 1994. 91(11): p. 4678-82. 
49. Hanson, K.D., et al., Effects of c-myc expression on cell cycle progression. Mol 
Cell Biol, 1994. 14(9): p. 5748-55. 
50. De Feo, M., et al., Rat carotid arteriotomy: c-myc is involved in negative 
remodelling and apoptosis. J Cardiovasc Med (Hagerstown), 2006. 7(1): p. 61-7. 
51. Andres, V. and C. Castro, Antiproliferative strategies for the treatment of 
vascular proliferative disease. Curr Vasc Pharmacol, 2003. 1(1): p. 85-98. 
52. Hahn, A.W., et al., Modulation of gene expression by high and low density 
lipoproteins in human vascular smooth muscle cells. Biochem Biophys Res 
Commun, 1991. 178(3): p. 1465-71. 
   
93 
53. Weiss, R.H. and H.E. Ives, Dissociation between activation of growth-related 
genes and mitogenic responses of neonatal vascular smooth muscle cells. 
Biochem Biophys Res Commun, 1991. 181(2): p. 617-22. 
54. Komuro, I., et al., Endothelin stimulates c-fos and c-myc expression and 
proliferation of vascular smooth muscle cells. FEBS Lett, 1988. 238(2): p. 249-
52. 
55. Naftilan, A.J., et al., Angiotensin II induces c-fos expression in smooth muscle via 
transcriptional control. Hypertension, 1989. 13(6 Pt 2): p. 706-11. 
56. Kipshidze, N., et al., Antisense therapy for restenosis following percutaneous 
coronary intervention. Expert Opin Biol Ther, 2005. 5(1): p. 79-89. 
57. von Rahden, B.H., et al., c-myc amplification is frequent in esophageal 
adenocarcinoma and correlated with the upregulation of VEGF-A expression. 
Neoplasia, 2006. 8(9): p. 702-7. 
58. Shchors, K., et al., The Myc-dependent angiogenic switch in tumors is mediated 
by interleukin 1beta. Genes Dev, 2006. 20(18): p. 2527-38. 
59. Pugh, C.W. and P.J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of the 
HIF system. Nat Med, 2003. 9(6): p. 677-84. 
60. Shi, Y., et al., Downregulation of c-myc expression by antisense oligonucleotides 
inhibits proliferation of human smooth muscle cells. Circulation, 1993. 88(3): p. 
1190-5. 
61. Marin, M.L., et al., Distribution of c-myc oncoprotein in healthy and 
atherosclerotic human carotid arteries. J Vasc Surg, 1993. 18(2): p. 170-6. 
62. Bennett, M.R., et al., Inhibition of vascular smooth muscle cell proliferation in 
vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest, 1994. 
93(2): p. 820-8. 
63. Kipshidze, N.N., et al., Advanced c-myc antisense (AVI-4126)-eluting 
phosphorylcholine-coated stent implantation is associated with complete vascular 
healing and reduced neointimal formation in the porcine coronary restenosis 
model. Catheter Cardiovasc Interv, 2004. 61(4): p. 518-27. 
64. de Nigris, F., et al., c-Myc oncoprotein: cell cycle-related events and new 
therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle, 2003. 
2(4): p. 325-8. 
65. Chan, K.H., et al., Vascular delivery of c-myc antisense from cationically 
modified phosphorylcholine coated stents. Biomaterials, 2007. 28(6): p. 1218-24. 
   
94 
66. Edelman, E.R., et al., c-myc in vasculoproliferative disease. Circ Res, 1995. 
76(2): p. 176-82. 
67. Mannion, J.D., et al., Saphenous vein graft protection: effects of c-myc antisense. 
J Thorac Cardiovasc Surg, 1998. 115(1): p. 152-61. 
68. Gardner, L., L. Lee, and C. Dang, myc oncogene, in The Encyclopedia of Cancer, 
B. Joseph., Editor. 2002, Academic Press: San Diego. 
69. Marcu, K.B., A.J. Patel, and Y. Yang, Differential regulation of the c-MYC P1 
and P2 promoters in the absence of functional tumor suppressors: implications 
for mechanisms of deregulated MYC transcription. Curr Top Microbiol Immunol, 
1997. 224: p. 47-56. 
70. Yang, D. and L.H. Hurley, Structure of the biologically relevant G-quadruplex in 
the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids, 2006. 25(8): p. 
951-68. 
71. Simonsson, T., P. Pecinka, and M. Kubista, DNA tetraplex formation in the 
control region of c-myc. Nucleic Acids Res, 1998. 26(5): p. 1167-72. 
72. Weinstein, I.B., Cancer. Addiction to oncogenes--the Achilles heal of cancer. 
Science, 2002. 297(5578): p. 63-4. 
73. Seenisamy, J., et al., The dynamic character of the G-quadruplex element in the c-
MYC promoter and modification by TMPyP4. J Am Chem Soc, 2004. 126(28): p. 
8702-9. 
74. Hurley, L.H., et al., Drug targeting of the c-MYC promoter to repress gene 
expression via a G-quadruplex silencer element. Semin Oncol, 2006. 33(4): p. 
498-512. 
75. Guo, Q.M., et al., Identification of c-myc responsive genes using rat cDNA 
microarray. Cancer Res, 2000. 60(21): p. 5922-8. 
76. Ellison, V. and B. Stillman, Biochemical characterization of DNA damage 
checkpoint complexes: clamp loader and clamp complexes with specificity for 5' 
recessed DNA. PLoS Biol, 2003. 1(2): p. E33. 
77. Arora, V., et al., c-Myc antisense limits rat liver regeneration and indicates role 
for c-Myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther, 
2000. 292(3): p. 921-8. 
78. Taylor, A.J., et al., Proliferative activity in coronary atherectomy tissue. Clinical, 
histopathologic, and immunohistochemical correlates. Chest, 1995. 108(3): p. 
815-20. 
   
95 
79. Malik, N., et al., Apoptosis and cell proliferation after porcine coronary 
angioplasty. Circulation, 1998. 98(16): p. 1657-65. 
80. Kida, I., R. Morishita, and T. Ogihara, [A new medical treatment for thrombosis 
by genetic engineering]. Nippon Rinsho, 1999. 57(7): p. 1519-25. 
81. Hochleitner, B.W., et al., Fluid shear stress induces heat shock protein 60 
expression in endothelial cells in vitro and in vivo. Arterioscler Thromb Vasc 
Biol, 2000. 20(3): p. 617-23. 
82. Xu, Q., et al., Serum soluble heat shock protein 60 is elevated in subjects with 
atherosclerosis in a general population. Circulation, 2000. 102(1): p. 14-20. 
83. Kleindienst, R., et al., Immunology of atherosclerosis. Demonstration of heat 
shock protein 60 expression and T lymphocytes bearing alpha/beta or 
gamma/delta receptor in human atherosclerotic lesions. Am J Pathol, 1993. 
142(6): p. 1927-37. 
84. de Graaf, R., et al., Human heat shock protein 60 stimulates vascular smooth 
muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect, 
2006. 8(7): p. 1859-65. 
85. Kol, A., et al., Chlamydial and human heat shock protein 60s activate human 
vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest, 
1999. 103(4): p. 571-7. 
86. Pockley, A.G., et al., Circulating heat shock protein 60 is associated with early 
cardiovascular disease. Hypertension, 2000. 36(2): p. 303-7. 
87. Sasu, S., et al., Chlamydia pneumoniae and chlamydial heat shock protein 60 
stimulate proliferation of human vascular smooth muscle cells via toll-like 
receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res, 
2001. 89(3): p. 244-50. 
88. Hirono, S., et al., Chlamydia pneumoniae stimulates proliferation of vascular 
smooth muscle cells through induction of endogenous heat shock protein 60. Circ 
Res, 2003. 93(8): p. 710-6. 
89. Wick, G., et al., Role of heat shock protein 65/60 in the pathogenesis of 
atherosclerosis. Int Arch Allergy Immunol, 1995. 107(1-3): p. 130-1. 
90. Menssen, A. and H. Hermeking, Characterization of the c-MYC-regulated 
transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc 
Natl Acad Sci U S A, 2002. 99(9): p. 6274-9. 
91. Kim, J.W., et al., HIF-1 and Dysregulated c-Myc Cooperatively Induces VEGF 
and Metabolic Switches, HK2 and PDK1. Mol Cell Biol, 2007. 
   
96 
92. Podar, K., et al., The small-molecule VEGF receptor inhibitor pazopanib 
(GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc 
Natl Acad Sci U S A, 2006. 103(51): p. 19478-83. 
93. Black, S.M., et al., Cyclic stretch increases VEGF expression in pulmonary 
arterial smooth muscle cells via TGF-1 and reactive oxygen species: a 
requirement for NAD(P)H oxidase. Conf Proc IEEE Eng Med Biol Soc, 2004. 7: 
p. 5053-6. 
94. Quinn, T.P., et al., Cyclic mechanical stretch induces VEGF and FGF-2 
expression in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell 
Mol Physiol, 2002. 282(5): p. L897-903. 
95. Inoue, M., et al., Vascular endothelial growth factor (VEGF) expression in human 
coronary atherosclerotic lesions: possible pathophysiological significance of 
VEGF in progression of atherosclerosis. Circulation, 1998. 98(20): p. 2108-16. 
96. Shibata, M., et al., The involvement of vascular endothelial growth factor and flt-
1 in the process of neointimal proliferation in pig coronary arteries following 
stent implantation. Histochem Cell Biol, 2001. 116(6): p. 471-81. 
97. Sadoshima, J., et al., Molecular characterization of the stretch-induced 
adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac 
hypertrophy. J Biol Chem, 1992. 267(15): p. 10551-60. 
98. Li, C., et al., Effects of fluid shear stress on expression of proto-oncogenes c-fos 
and c-myc in cultured human umbilical vein endothelial cells. Clin Hemorheol 
Microcirc, 2002. 26(2): p. 117-23. 
99. Hsieh, H.J., N.Q. Li, and J.A. Frangos, Pulsatile and steady flow induces c-fos 
expression in human endothelial cells. J Cell Physiol, 1993. 154(1): p. 143-51. 
100. Banes, A.J., et al., A new vacuum-operated stress-providing instrument that 
applies static or variable duration cyclic tension or compression to cells in vitro. 
J Cell Sci, 1985. 75: p. 35-42. 
101. Banes, A.J., et al., Culturing cells in a mechanically active environment. Am 
Biotechnol Lab, 1990. 8(7): p. 12-22. 
102. Gilbert, E. and T.S. Hakim, Derivation of pulmonary capillary pressure from 
arterial occlusion in intact conditions. Crit Care Med, 1994. 22(6): p. 986-93. 
103. Lee, A.A., et al., An equibiaxial strain system for cultured cells. Am J Physiol, 
1996. 271(4 Pt 1): p. C1400-8. 
104. Sotoudeh, M., et al., A strain device imposing dynamic and uniform equi-biaxial 
strain to cultured cells. Ann Biomed Eng, 1998. 26(2): p. 181-9. 
   
97 
105. Ives, C.L., S.G. Eskin, and L.V. McIntire, Mechanical effects on endothelial cell 
morphology: in vitro assessment. In Vitro Cell Dev Biol, 1986. 22(9): p. 500-7. 
106. Sadoshima, J., et al., Roles of mechano-sensitive ion channels, cytoskeleton, and 
contractile activity in stretch-induced immediate-early gene expression and 
hypertrophy of cardiac myocytes. Proc Natl Acad Sci U S A, 1992. 89(20): p. 
9905-9. 
107. Holzapfel, G.A. and H.W. Weizsacker, Biomechanical behavior of the arterial 
wall and its numerical characterization. Comput Biol Med, 1998. 28(4): p. 377-
92. 
108. Smeets, E.F., et al., A comparison of substrates for human umbilical vein 
endothelial cell culture. Biotech Histochem, 1992. 67(4): p. 241-50. 
109. Frye, S.R., et al., cDNA microarray analysis of endothelial cells subjected to 
cyclic mechanical strain: importance of motion control. Physiol Genomics, 2005. 
21(1): p. 124-30. 
110. Wilfinger, W.W., K. Mackey, and P. Chomczynski, Effect of pH and ionic 
strength on the spectrophotometric assessment of nucleic acid purity. 
Biotechniques, 1997. 22(3): p. 474-6, 478-81. 
111. Rozen, S. and H. Skaletsky, Primer3 on the WWW for general users and for 
biologist programmers. Methods Mol Biol, 2000. 132: p. 365-86. 
112. Alberts, B., Molecular biology of the cell. 4th ed. 2002, New York: Garland 
Science. 1463. 
113. Chen, A.H., et al., Cyclic strain activates the pro-survival Akt protein kinase in 
bovine aortic smooth muscle cells. Surgery, 2001. 130(2): p. 378-81. 
114. Sotoudeh, M., et al., Induction of apoptosis in vascular smooth muscle cells by 
mechanical stretch. Am J Physiol Heart Circ Physiol, 2002. 282(5): p. H1709-16. 
115. Cohen, C.R., et al., Activation of the adenylyl cyclase/cyclic AMP/protein kinase 
A pathway in endothelial cells exposed to cyclic strain. Exp Cell Res, 1997. 
231(1): p. 184-9. 
116. Mayr, M., et al., Biomechanical stress-induced apoptosis in vein grafts involves 
p38 mitogen-activated protein kinases. Faseb J, 2000. 14(2): p. 261-70. 
117. Dean, M., et al., Regulation of c-myc transcription and mRNA abundance by 
serum growth factors and cell contact. J Biol Chem, 1986. 261(20): p. 9161-6. 
118. Thompson, C.B., et al., Levels of c-myc oncogene mRNA are invariant throughout 
the cell cycle. Nature, 1985. 314(6009): p. 363-6. 
   
98 
119. Pandey, S. and E. Wang, Cells en route to apoptosis are characterized by the 
upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling 
events of early cell-cycle traverse. J Cell Biochem, 1995. 58(2): p. 135-50. 
120. Pommier, R.F., et al., Cytotoxicity of dimethyl sulfoxide and antineoplastic 
combinations against human tumors. Am J Surg, 1988. 155(5): p. 672-6. 
121. Mata-Greenwood, E., et al., Cyclic stretch increases VEGF expression in 
pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen 
species: a requirement for NAD(P)H oxidase. Am J Physiol Lung Cell Mol 
Physiol, 2005. 289(2): p. L288-9. 
122. Kakisis, J.D., C.D. Liapis, and B.E. Sumpio, Effects of cyclic strain on vascular 
cells. Endothelium, 2004. 11(1): p. 17-28. 
123. Ingber, D.E., Cellular tensegrity: defining new rules of biological design that 
govern the cytoskeleton. J Cell Sci, 1993. 104 ( Pt 3): p. 613-27. 
124. Xie, J., J. Zhou, and Y.C. Fung, Bending of blood vessel wall: stress-strain laws 
of the intima-media and adventitial layers. J Biomech Eng, 1995. 117(1): p. 136-
45. 
125. Jonas, J.C., et al., High glucose stimulates early response gene c-Myc expression 
in rat pancreatic beta cells. J Biol Chem, 2001. 276(38): p. 35375-81. 
126. Davies, P.F. and S.C. Tripathi, Mechanical stress mechanisms and the cell. An 
endothelial paradigm. Circ Res, 1993. 72(2): p. 239-45. 
127. Dang, C.V., et al., The c-Myc target gene network. Semin Cancer Biol, 2006. 
16(4): p. 253-64. 
128. Yoshio, Y., et al., TNP-470, an angiogenesis inhibitor, suppresses the 
progression of peritoneal fibrosis in mouse experimental model. Kidney Int, 2004. 
66(4): p. 1677-85. 
129. Woo, S.H., et al., Diarsenic and tetraarsenic oxide inhibit cell cycle progression 
and bFGF- and VEGF-induced proliferation of human endothelial cells. J Cell 
Biochem, 2005. 95(1): p. 120-30. 
130. Sutherland, S., Cell cycle inhibitors key to neoangiogenesis. Drug Discov Today, 
2005. 10(15): p. 1015-6. 
131. Iordanskiy, S., et al., Heat shock protein 70 protects cells from cell cycle arrest 
and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J 
Virol, 2004. 78(18): p. 9697-704. 
132. Farb, A., et al., Oral everolimus inhibits in-stent neointimal growth. Circulation, 
2002. 106(18): p. 2379-84. 
   
99 
133. Barron, V., et al., The effect of physiological cyclic stretch on the cell 
morphology, cell orientation and protein expression of endothelial cells. J Mater 
Sci Mater Med, 2007. 18(10): p. 1973-81. 
134. Magid, R., T.J. Murphy, and Z.S. Galis, Expression of matrix metalloproteinase-9 
in endothelial cells is differentially regulated by shear stress. Role of c-Myc. J 
Biol Chem, 2003. 278(35): p. 32994-9. 
135. Milkiewicz, M., et al., Static strain stimulates expression of matrix 
metalloproteinase-2 and VEGF in microvascular endothelium via JNK- and ERK-
dependent pathways. J Cell Biochem, 2007. 100(3): p. 750-61. 
136. Fingerle, J., et al., Role of platelets in smooth muscle cell proliferation and 
migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A, 
1989. 86(21): p. 8412-6. 
137. Wedgwood, S., et al., Fibroblast growth factor-2 expression is altered in lambs 
with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res, 
2007. 61(1): p. 32-6. 
 
 
